About: acn

香港, 2025年3月24日 - (亞太商訊 via SeaPRwire.com) - 周大福人壽今天欣然宣佈，推出「灣區門診通」保障計劃（「灣區門診通」/ 「計劃」），讓經常往返港澳及指定大灣區城市*的客戶，獲享周大福企業旗下的大灣區醫療集團強大醫療網絡所提供的便捷和優質的醫療服務，充分發揮集團多元業務體系優勢，為客戶帶來優質體驗，持續開創保險新價值。周大福人壽更成為首家與大灣區醫療集團合作提供中醫門診服務的保險公司。計劃設有三個級別，覆蓋指定大灣區城市*以至香港及澳門，提供市場首創1一個計劃可為客戶及最多兩位指定家屬2提供中西醫門診治療、牙科洗牙及健康管理增值服務。「灣區門診通」涵蓋一系列服務，包括線上3,4線下普通科醫生診症3,5連最多三天處方基本藥物、中醫門診3,6與牙科洗牙3,7以及兩項增值服務 : 主動式健康管理3,8及慢性疾病管理計劃3,9，一站式照顧客戶及其家人2在篩查、持續監察至健康教育等範疇的需要，提供可信任、可負擔、可觸及的健康管理服務，為客戶及其家庭健康打下穩固的基礎，讓他們安心穿梭大灣區。周大福人壽早於去年初已與大灣區醫療集團結成策略合作夥伴，並與其旗下大灣區三甲醫院組成三方聯盟，為客戶提供一站式優質醫療服務，不僅有效提高醫療效率、降低醫療開支，更可提升客戶服務體驗。這次進一步深化合作，積極支持特區政府發展大灣區的舉措，為經常北上南下的客戶提供高質素的醫療服務。周大福人壽首席產品總監關珮妍表示：「隨着粵港澳大灣區的急速發展，巿場對跨地域的醫療保障需求殷切。『灣區門診通』特別針對客戶不斷變化的生活方式，以及越趨普及中西治療的融合概念，讓粵港澳大灣區客戶及其家人可受惠於集團多元業務體系，獲享由大灣區醫療集團提供的優質中西醫療服務。計劃引入市場首創1的一家三保保險方案，只需投保一個計劃，客戶及其家人2可共用計劃服務下中西醫門診及牙科洗牙等服務，充分體現周大福人壽以人為本、以客為先的服務承諾。周大福人壽更成為首家保險公司與大灣區醫療集團合作，提供中醫門診服務，提升客戶對醫療服務的體驗。我們期待繼續與大灣區醫療集團加強協作，在未來推出更多迎合客戶需求的服務，開創健康新價值。」大灣區醫療集團聯席行政總裁李家聰博士則表示：「大灣區醫療集團與周大福人壽的深入合作，是順應跨境生活及養老趨勢的切實舉措，也是雙方踐行『保險+醫療』融合創新的積極探索。通過『灣區門診通』，客戶及其家人可預約符合國際標準的GOLDTM金牌家庭醫生，獲享粵港澳三地全科門診、指定大灣區城市*中醫門診、視頻問診、慢病管理、主動式健康管理等服務，以及跨境直付的便利。大灣區醫療集團基於從預防到治療的全程服務能力，廣泛的跨境服務網絡以及粵港澳醫療資源優勢，為周大福人壽的客戶提供覆蓋粵港澳三地、服務三代人的一站式、連續性健康管理服務，助力灣區家庭實現從疾病預防到健康傳承的全週期守護。未來，我們將依託已建立的專業、可信任的醫療體系及標準，共同推動大灣區特色價值醫療的發展，繼續攜手開創更多以客戶為中心的健康管理方案。」計劃的核心特點包括：1) 市場首創1一家三保保險方案：- 計劃為客戶及其最多兩位指定家屬2提供保障，周全照顧家庭的需要，為客戶提供全面的健康保障和日常生活中所需的醫療支持。2) 線上3,4線下普通科醫生診症服務：- 無論選擇面診還是網上診症，受保人及指定家屬2均可獲得最多三天的處方基本藥物以及免費快遞服務 (只適用於網上診症)。計劃設有三個級別，面診服務的醫療網絡範圍覆蓋指定大灣區城市*以至香港及澳門。- 投保計劃三更可享無限次接受於中國內地醫療網絡之指定診所的普通科醫生網上診症及藥物快遞服務10。3) 中醫門診與牙科洗牙服務：- 客戶可因應個人需要選擇中西合璧治療，只要經由大灣區醫療集團GOLDTM金牌醫生轉介，即可於指定的大灣區城市*內的中醫診所接受中醫治療，包括診症、診斷，並可獲得最多三天的處方中藥及相關中醫醫療服務。- 計劃亦提供每年一次洗牙及保健服務。4) 健康管理增值服務：- 主動式健康管理 : 貼心服務由大灣區醫療集團GOLDTM金牌醫生及護士進行，涵蓋家族病史評估、健康目標設定、疾病預防教育、健康生活方式建議等，根據客戶需要提供後續跟進。- 慢性疾病管理計劃 : 由大灣區醫療集團GOLDTM金牌醫生及護士為客戶及家人提供慢性疾病預防教育，包括健康檢查預約、糖尿病篩查、藥物控制及健康生活方式建議，以達至「早預防、早發現、早治療」的目的。周大福人壽推出「灣區門診通」保障計劃，讓經常往返港澳及指定大灣區城市*的客戶，獲享由大灣區醫療集團強大醫療網絡所提供的便捷和優質的醫療服務，充分發揮集團多元業務體系優勢。左起 : 周大福人壽首席產品總監關珮妍、周大福人壽首席策略總監歐陽明欣、大灣區醫療集團聯席行政總裁李家聰博士、大灣區醫療集團首席保險官方以棟。註：*是指中華人民共和國廣東省內6 個城市，包括廣州、深圳、珠海、佛山、東莞及中山。1.「市場首創」特點是指計劃可讓受保人自己及最多兩位指定家屬共享計劃服務，且計劃服務同時提供西醫及中醫門診、牙科洗牙以及健康管理增值服務。「市場首創」乃比較香港主要人壽保險公司同類主要保障計劃後所得出之結果，資料截至2025年3月24日。2.家人 / 指定家屬即保單持有人（即受保人）於投保或續保時指定的最多 2 位直系家屬（即保單持有人的合法配偶、子女或父母 )。指定家屬於同一保單年度內不能作出更改。受保人繕發年齡由18至80歲，指定家屬繕發年齡由初生15日至80 歲。3.就每次門診服務診症，受保人或指定家屬須支付20港元 / 20澳門元 / 人民幣8 元之共付費。如受保人及 / 或指定家屬於門診服務及健康管理增值服務中所提及之任何診症時接受由大灣區醫療集團所提供不在本計劃涵蓋服務範圍內之任何醫療服務、治療及 / 或藥物，受保人及 / 或指定家屬將需要自行承擔該等醫療服務、治療及 / 或藥物的費用。4.普通科醫生網上診症服務只適用於於網上診症當天已年滿 7 歲或以上的受保人及 / 或指定家屬。受保人或指定家屬可選擇接受由大灣區醫療集團的中國內地醫療網絡之指定診所的註冊醫生作出的網上診症及提供為期最多 3 天的處方基本藥物連基本藥物快遞服務，惟受保人或指定家屬的地址必須處於與提供網上診症的註冊醫生的診所位置相同之地區內。若在網上診症時，受保人或指定家屬與該註冊醫生身處不同地區，此計劃服務將不涵蓋該網上診症或任何門診服務，本公司亦無需負責受保人或指定家屬因此而蒙受的損失。5.受保人及 / 或指定家屬可於大灣區醫療集團的指定大灣區城市、香港或澳門 ( 受限於產品小冊子內計劃一覽表中根據不同計劃級別所列明的服務地域 ) 內醫療網絡之指定診所，接受醫療網絡的註冊醫生以門診方式作出的面對面診症及提供為期最多 3 天的處方基本藥物。6.若受保人及 / 或指定家屬因傷病，經大灣區醫療集團 GOLDTM金牌醫生確認為醫療必需接受中醫治療而作出首次轉介後，受保人或指定家屬可於大灣區醫療集團指定大灣區城市內之醫療網絡的指定中醫診所就該傷病接受中醫治療服務，包括診症、診斷、為期最多 3 天的處方中藥以及相關的中醫醫療服務及治療，每次門診診症費用上限為人民幣 100 元。7.受保人或指定家屬可於大灣區醫療集團的指定牙科服務中心接受每保單年度共 1 次的洗牙及保健服務。8.於受保人及 / 或指定家屬完成登記此計劃服務後，大灣區醫療集團將會主動聯絡受保人及 / 或指定家屬，獲其同意後，大灣區醫療集團 GOLDTM金牌醫生將會安排為受保人及 / 或指定家屬以面對面或網上診症形式進行首次主動式健康管理評估。首次主動式健康管理評估及每次任何其後的跟進評估將分別視為 1 次門診診症，並受限於門診服務每保單年度上限。9.大灣區醫療集團將為患者進行慢性疾病預防教育，此服務由大灣區醫療集團 GOLDTM金牌醫生及護士為受保人及 / 或指定家屬提供並受限於中國內地醫療網絡。受保人及 / 或指定家屬就此慢性疾病管理計劃而到訪大灣區醫療集團醫療網絡診所及 / 或服務中心將不會視為接受門診服務，並不受限於門診服務每保單年度上限。10.就超出門診服務之每保單年度上限後的普通科醫生網上診症，受保人或指定家屬需自行承擔藥物及快遞費用。重要提示：- 本新聞稿乃資料摘要，僅供參考之用。詳情請參閱有關產品小冊子、宣傳單張及保單文件。有關周大福人壽「灣區門診通」保障計劃詳情，均以此計劃之條款及保障作準。- 本新聞稿的產品資料不包含「灣區門診通」保障計劃的完整條款，有關完整條款載於保單文件中。上述「灣區門診通」保障計劃可作為獨立保單而無須捆綁式地與其他種類的保險產品一併購買。敬請務須參閱有關「灣區門診通」保障計劃之主要產品推銷刊物、保單條款及由閣下的持牌保險中介人所陳述之說明文件以全面了解關於以上定義、收費、產品特點、不保事項及賠償給付條件等之詳情及完整條款及保障。- 有關「灣區門診通」保障計劃產品小冊子，請瀏覽: https://www.ctflife.com.hk/pdf/tc/products/life-insurance/health/gba-mediaccess-product-brochure.pdf- 如欲查詢，歡迎致電周大福人壽客戶服務熱線：+852 2866 8898。- 本新聞稿只適宜於香港分發，不應被詮釋為在香港以外地區提供周大福人壽的任何產品，或就其作出要約或招攬。 如在香港境外之任何司法管轄區的法律下提供或出售或游說購買任何周大福人壽的產品屬違法，周大福人壽在此聲明無意在該司法管轄區提供或出售或游說購買該產品。關於周大福人壽保險有限公司周大福人壽保險有限公司（「周大福人壽」）扎根香港 40 年，為周大福創建有限公司（香港股份代號：659）的全資附屬公司，也是香港最具規模的壽險公司之一。作為周大福企業成員，周大福人壽緊扣鄭氏家族（「周大福集團」或「集團」）多元業務體系的雄厚資源，致力為客戶及其摯愛家人於「生活、成長、健康、傳承」的人生旅程中，提供個人化的匠心規劃、 終身保障及優質體驗。憑藉集團財務實力及環球投資佈局，周大福人壽矢志成為亞太區領先的保險公司，持續開創保險新價值。關於大灣區醫療集團大灣區醫療集團成立於2014年，是一家使命驅動型的香港醫療企業。集團由鄭裕彤家族辦公室 -- 周大福企業有限公司進行控股戰略投資。自成立以來，集團與粵港澳大灣區多地政府合作，開創私營與公立合作（Private Public Partnership）的醫療服務模式，目前已攜手各地政府培養逾3,500名GOLDTM金牌全科醫護，共建逾220家GOLDTM公私合營診所，及在大型公立三甲醫院攜手運營GOLDTM港澳居民健康服務中心，提供全方位的門診及住院服務，憑藉GOLDTM金牌家庭醫生服務帶來的預防醫學和健康管理優勢，與國際保險公司攜手研發集門診+住院服務於一體的創新型跨境醫療險產品，推動價值醫療（Value-Based Care）模式在大灣區的發展。大灣區醫療集團的目標是讓所有人獲得可信任且可負擔的醫療服務，從而在不用擔憂健康的考慮下追求自己的夢想。傳媒聯絡周大福人壽品牌發展及傳訊部陳佳容+852 2591 8504deronie.tan@ctflife.com.hk周大福人壽保險有限公司（於百慕達註冊成立之有限公司） Copyright 2025 亞太商訊 via SeaPRwire.com.

香港, 2025年3月24日 - (亞太商訊 via SeaPRwire.com) - 中國領先的殯葬服務提供者 -- 福壽園國際集團有限公司(「福壽園」或「公司」，連同其附屬公司，統稱「集團」；股份代號：1448) 公佈截至2024年12月31日止年度 (「本年度」) 之全年業績。2024年，中國經濟整體穩定運行，長期向好。隨著中國全面步入小康社會，站在了新的歷史起點上，推動民生福祉達到新水準、不斷增強人民群眾獲得感、幸福感、安全感將是中國在民生領域未來發展的主要目標。進入了新時代，人民群眾對美好生活的嚮往從「生」延伸到「死」，提升人民群眾身後事的服務質量、實現「逝有所安」已成為殯葬領域重大時代課題，並不斷推動中國殯葬行業向縱深發展。然而，在另一方面，隨著外部環境更趨複雜嚴峻和不確定，殯葬情景中客戶的消費行為趨向謹慎，疊加去年同期在疫情後被累積和遞延的市場消費需求快速釋放形成的高基數，都給今年集團的發展帶來了挑戰。但在全集團員工的齊心努力下，於本年度內，集團總收益達人民幣2,077.5百萬元。本公司擁有人應佔溢利及全面收入達人民幣373.1百萬元。福壽園國際集團有限公司董事局主席兼執行董事白曉江先生表示:「在2024年，為應對經濟大環境和客戶消費行為的相應變化趨勢，集團從市場和產品的雙重維度持續關注，在服務延展、科技引領、文化創新等領域多點發力，因「園」施策，著力滿足墓園客戶多元化、差異化，特別是精神層面的消費需求，持續提升產品和服務的核心競爭力，實現集團長期可持續發展。同時，集團持續秉承「以人為本、文化為根」的理念，正在從行業領先的殯葬綜合服務商轉型為生命科技服務提供者，從物理世界「福壽園」向精神世界「福壽元」發展。致力於把「記號做美，記載做厚，紀念做長」。」福壽園持續秉承「以人為本、文化為根」的理念，正在從行業領先的殯葬綜合服務商轉型為生命科技服務提供商，從物理世界「福壽園」向精神世界「福壽元」發展。集團致力於把「記號做美，記載做厚，紀念做長」。本年度，全網涉「福壽園」相關信息共計約11.4萬條，同比增長74%，全網報導量、正面報導量均創歷年新高。社會普遍認可福壽園AI數字化探索，群眾點讚北京大學清明論壇、數智人虛擬清明發佈會、福壽園生命公益節等品牌活動及產教融合、生命教育等公益踐行，並多媒體地宣傳集團內各地禮儀師、墓碑設計師、保潔員等從業人員，稱之為「種星星的人」。回顧期內，集團在公益事業、公共關系、科技創新、品牌發展方面的表現獲得社會各界認可，先後獲得第十三屆公益節「年度教育公益貢獻獎」、第八屆中國公益年會「年度中國公益企業」、第十三屆財經峰會「數智化創新引領獎」及「傑出品牌形象獎」、第七屆社會責任大會「年度責任金獎」等榮譽。在2025年1月，福壽園受邀參加2025達沃斯世界品牌峰會，入圍「2024世界創新品牌500強」，福壽園品牌價值獲評價29.16億美元（約人民幣212億元），品牌指數高達492.45分，排名第380位。截至目前，集團的業務已進入十九個省、自治區、直轄市的四十餘座城市，其中包括正在運營的位於全國十七個省的主要城市、直轄市和自治區的墓園和殯儀設施。集團在全國其他重要省份、省會城市及空白區域的拓展計劃仍在穩步推進中。集團將以審慎和穩健的步伐，堅守對股東負責的態度，聚焦核心高能級城市，關注更具區域協同效應的新建及存量項目的機會，篩選合適的目標，整合多元業務資源，以公允合理的對價收購優質資產。持續落實「3JI」理念 科技賦能管理集團正在從行業領先的殯葬綜合服務商轉型為生命科技服務提供商，在墓園業務領域，持續致力於落實「3JI」理念在各地、各墓園的應用。回顧期內，在「3JI」理念的導引下，集團推出了墓穴產品+服務的新情緒整合產品，致力於為生命提供創新、藝術和更多維度的服務與滿足。以「3JI」理念設計並成功落地的17家墓園園區，藝術美學得到了深刻的表達，從飽含人文關懷態度的設計理念到內外兼修的園區整體構造，從作為修飾性的自然景觀到功能性和藝術性共存的碑體形態，對生命的敬畏和對生命美學的追求均得以彰顯。此外，作為「3JI」理念中記載和紀念活動的體現，包括數字禮祭（數字化沉浸式落葬、追思及禮祭）、「福壽園服務在線」小程序、數字人文紀念館、人生回憶錄和數位家祠等在內的個性化、數字化創新服務已被開發整合在殯、葬、祭等多個場景和環節，使得客戶可通過上傳聲音、圖片和視頻等材料，完成二維和三維數字人模型、人生微電影、人生回憶錄的製作，以及以家庭為單位的家傳的生成，均給客戶帶來更加豐富、立體的情感體驗和有益的情緒干預。同時，在數字時代下，集团強化了科技賦能管理，在各墓園企業中，我們已全面推行工程、保安、保潔以及園區管理的數字化系統，配合人效目標的實施，進一步提升了運營效率。回顧期內，在國內建築行業整體下行的大環境下，本集團設計板塊的全資子公司天泉佳境專注殯葬領域的規劃設計，仍保持了較為穩定的經營和發展。天泉佳境通過市場公開招標在本年度獲得多地殯葬設施的規劃設計業務，其設計實力及經營能力在國內仍保持領先地位。同時，在集團內部，天泉佳境積極踐行「3JI」理念，為集團各實體公司的「3JI」規劃與落地，提供了強有力的保障，進一步增強集團產品在市場上的競爭力。核心流程改造 實現現代殯儀的「新消費」需求回顧期內，集团著重在業務結構調整、客戶價值創造、禮儀服務轉型和科技賦能管理幾個方面開展工作。通過以「新場景、新用品、新服務」為主的核心流程改造，實現現代殯儀的「新消費」需求，激發傳統殯儀業務的活力，滿足市場差異化、多元化的服務需求，引領行業發展。充分關注客戶心理需求，利用智能聲光系統改造火化場景，將「冥想療愈」服務引入告別儀式；研發安靈接運儀式、故人沐禮、懸掛祈福禮及相關文創產品；廳堂標準化的進一步升級形成《生命「四堂」規劃方案》，提升守靈告別廳的實用性、美觀度、科技感，增強客戶對殯儀服務的體驗感和獲得感。同時，集团進一步擴大殯儀用品集中研發和集中採購範圍，將「文化紙棺」、「文化靈盒」、「隨行香囊」等嵌入到儀式中，確保殯儀「新文化」全覆蓋。此外，集团持續推進技術含量高，如防腐和古人沐浴等高附加值服務的推廣，強化自身的核心競爭力，助推殯儀服務高質量可持續發展。在人口老齡化的社會背景下，生前契約服務正吸引更多希望儘早安排好自己身後事的客戶群，亦得到各級政府及長者服務機構的肯定、支持和服務採購。本年度內，累計簽訂生前契約20,229份合約（二零二三年：17,707份合約），較上年增長14.2%。自研環保智慧火化設備 降低運維成本回顧期內，集團繼續優化環保火化設備產品性能，持續收集客戶回饋，進一步提高產品質量，降低運維成本。集团積極維持國內外客戶，做好售前技術支持、售後維修保障工作，研發並提供了舊式JS-2火化爐更新改造服務，以使得現有客戶可以分享最新的產品升級和能耗節約成果。同時，集團持續對新型揀灰爐、尾氣淨化系統設備進行數據統計分析驗證，不斷優化調整，進一步降低火化時長和燃料消耗。此外，集團亦在建立環保火化設備板塊自身的國內外銷售體系。本年度內，集團與國內外多家潛在合作方保持密切聯系，亦與多家簽訂了火化機、尾氣系統和若干輔助設備的銷售合作協議。 Copyright 2025 亞太商訊 via SeaPRwire.com.

香港, 2025年3月24日 - (亞太商訊 via SeaPRwire.com) - 中信國際電訊集團有限公司（「中信國際電訊」，香港交易所股份代號：1883）全資擁有的中信國際電訊(信息技術) 有限公司(「中信國際電訊CPC」)宣布與深信服科技股份有限公司(「深信服」SANGFOR) 攜手深化策略夥伴關係，融合深信服的技術與中信國際電訊CPC創新ICT服務能力，共建創新、合規與安全的信創混合雲服務。全新SmartCLOUD™ C-FUSION 信創混合雲系列，融合全棧SmartCLOUD™ 專屬私有雲、虛擬私有雲与公有雲服务, 為企業客戶提供一個更自主可控，兼容不同技術架構的雲基礎設施和系統組合，推動企業數字化轉型，重新定義企業IT資源管理方式，支援其在中國及全球市場的無縫營運。左起：中信國際電訊CPC代表郭偉基(商務總裁) 和黄志强(產品及數智發展部副總裁) ，以及深信服代表姚成志（成熟亞太地區業務總經理）和贾磊（國際市場業務經理）近年隨著政策支持及行業需求共振，不但推動了重點行業信息系統更新要求，同時也加速企業信創化發展和服務多樣化佈局。中信國際電訊CPC作爲企業數字化轉型的核心數智夥伴，擁有豐富的雲網安服務資源及解決專案落地經驗，在信創浪潮下，積極協助客戶實現數智化升級與信創化部署，並攜手其技術夥伴深信服共築信創雲服務新格局。深信服在超融合基礎設施（HCI）市場中佔據領先地位，HCI解決方案憑藉高性能、高可靠性和易用性，廣泛應用於政府、金融、醫療、教育等多個行業。深信服全棧自主的信創超融合架構強化了中信國際電訊CPC 現有綜合雲服務能力, 雙方此次策略合作將共建符合信創要求的混合雲解決方案，為企業提供更靈活、可持續的混合雲解決方案，助力企業提升競爭優勢。強強聯手 共創自主可信雲時代SmartCLOUD™ C-FUSION混合雲系列支持「一雲多芯」架構，全棧信創雲平台能兼容多種CPU架構與應用需求，構建硬核安全，強化合規性應用，確保多元混合雲平台貫穿信創生態系统，軟硬件環境无缝適配，統一承載、統一管理。加速企業數字化進程，為企業創造更大價值。雙方合作將率先落地北京與廣州市場，為當地企業提供高品質的雲計算服務，並計劃未來逐步拓展至更多區域，攜手推動企業數字化轉型的全面升級。中信國際電訊CPC 產品及數智發展部副總裁黃志強表示：「我們致力與創新生態圈夥伴包括深信服攜手發展，此次的深化合作體現了我們致力於提供創新、可擴展的IT解決方案的承諾。借助深信服的技術優勢，進一步優化了中信國際電訊CPC的服務能力，相信全新的SmartCLOUD C-FUSION 系列， 包括SmartCLOUD C-Compute及SmartCLOUD C-vONE, 有效助力企業通過單一平台應對複雜的IT基礎設施挑戰，降低成本。憑藉中信國際電訊CPC"服務在地，連接全球"的優勢，配合企業'出海進華'戰略，更可實現無縫接入，在跨地區的雲平台之間互聯互通。我們將繼續提供定制化解決方案，為在中國營運、連接中國以至拓展全球市場的企業帶來更高價值。」深信服科技股份有限公司成熟亞太地區業務總經理姚成志表示：「中信國際電訊CPC憑藉其卓越的合作表現，最近榮獲深信服'鉑金合作夥伴'獎項，彰顯雙方緊密的合作關係。此次戰略合作將充分發揮雙方優勢，不僅提升產品與服務的供應能力，更有助於我們拓展全球市場。中信國際電訊CPC廣泛的全球基礎設施覆蓋，結合深信服在安全與雲計算領域的前沿技術，將為不同地區與行業的數字化轉型提供強大支持，進一步增強市場競爭優勢。」SmartCLOUD™ C-FUSION 賦能合規與業務持續性發展SmartCLOUD C-FUSION混合雲系列具備"一雲多芯"架構，支援X86, 华为鲲鹏及海光C86 多種晶片架構與應用同時運行和無縫對接, 降低日後應用信創化遷移與轉換成本。此方案由中信國際電訊CPC全面管理，為進華企業提供符合信創政策要求的認可技術架構及軟硬件環境，適用於對要求自主可控技術有合規要求的企業，不僅確保業務持續性發展，更能滿足企業"出海進華"及未來IT發展的多元化需求。賦能企業「出海進華」戰略，拓展全球市場機遇中信國際電訊CPC與深信服的戰略合作，為企業提供了強大的混合雲解決方案，助力其實現「出海進華」的雙向戰略目標。通過SmartCLOUD C-FUSION混合雲系列, 包括SmartCLOUD C-Compute虛擬私有雲及SmartCLOUD C-vONE專屬私有雲解決方案，企業能夠在中國及全球市場以更有效成本無縫部署和管理IT雲資源，同時享有具備高可靠性、安全性與合規性，滿足各地區的監管要求。對於進軍中國市場的企業，可憑藉雙方合作優勢，提供本地化的雲計算服務，合規性確保高效運營與快速業務落地；對於出海企業，則可借助中信國際電訊CPC的全球網絡覆蓋，實現跨區域資源整合與靈活擴展。這次合作不僅降低了企業的IT複雜性與成本，更為其全球擴張提供了堅實的技術基礎，賦能企業"跨國跨地跨平台"發展，助力企業在國際競爭中脫穎而出。中信國際電訊CPC簡介中信國際電訊（信息技術）有限公司（「中信國際電訊CPC」）是中信國際電訊集團有限公司（香港交易所股份代號：1883）的全資附屬公司，一直矢志透過先進技術及旗艦解決方案，包括TrueCONNECT™專用網絡服務、TrustCSI信息安全解決方案、DataHOUSE全球統一雲數據中心解決方案及SmartCLOUD雲端運算解決方案，為全球跨國企業提供綜合數碼解決方案，滿足不同行業的ICT服務需求。憑借「創新-不斷」的服務理念，中信國際電訊CPC積極利用創新技術，提煉"技術賦能"，將人工智能、擴增實境、大數據，物聯網和其他尖端新興技術，融合深度學習及智能數據分析技術，轉化為"數據賦能"生成式AI+應用，重塑企業智能營運之旅。中信國際電訊CPC以「服務在地，連接全球」的優勢，承諾為客戶提供最優質的一站式ICT服務。全球化網絡資源連接近170個服務據點、60多個SDWAN 網關；20個雲服務中心、30多個數據中心及3個全天候運作的安全運作中心，服務遍布逾160個國家和地區，無縫連接亞洲、歐美、非洲、中東以及中亞等地區。透過全球化服務佈局，多年不斷深耕各個行業與領域經驗，一系列國際認證（SD-WAN Ready, ISO 9001、14001、20000、27001 及27017），確保為企業提供國際化標準及專業在地服務能力，成為客戶信賴的信息智能化服務供應商。請瀏覽www.citictel-cpc.com獲取更多資訊。深信服簡介深信服科技股份有限公司是專注於企業級網絡安全、雲計算、IT基礎設施及物聯網的産品和服務供應商，擁有深信服智安全和信服雲兩大業務品牌，致力於承載各行業用戶數字化轉型過程中的基石性工作，從而讓每個用戶的數字化更簡單、更安全。目前，深信服員工規模超8000名，在全球有70餘個分支機構，公司先後被評爲國家級高新技術企業、中國軟件和信息技術服務綜合競爭力百強企業等。一直以來，深信服十分重視研發和創新。持續將20%+年收入投入研發，並在深圳、北京、長沙、南京和成都設立5大研發中心，研發人員比例約為40%，堅持以"持續創新"的理念打造省心便捷的産品。目前，超過10萬家用戶正在使用深信服的産品。根據IDC數據，深信服VPN、全網行爲管理、超融合、應用交付、零信任、安全托管服務MSS和桌面雲均爲中國市佔率第一，下一代防火牆、aEs也均爲中國市佔率前三。在AI技術的先進研發和應用方向上，深信服持續加大投入，發佈了國內網絡安全領域的首個自研安全大模型--安全GPT、率先發佈自研AI算力平台（AICP）等領先産品。請瀏覽www.sangfor.com獲取更多資訊。傳媒查詢：Catherine Yuen中信國際電訊CPC(852)2170 7536電郵：catherine.yuen@citictel-cpc.com Copyright 2025 亞太商訊 via SeaPRwire.com.

Key Findings:KOCH DLE Process achieves an average lithium recovery rate of 98%Key brine contaminants average rejection greater than 99%, resulting in low purification production costsIndustry leading Lithium Chloride concentration attainedLi:TDS ratio of up to 0.129, averaging 0.126, significantly above the target Li:TDS of 0.08, expected to lower the cost with less evaporation during the EV battery grade purification process43,500 gallons (165,000 litres) of high purity lithium chloride was produced that meet or exceeded the specifications required by downstream processorsNEWPORT BEACH, CA, Mar 25, 2025 - (ACN Newswire via SeaPRwire.com) - Anson Resources Limited (ASX:ASN) ("Anson" or the "Company"), through its 100% owned subsidiary in the USA, A1 Lithium Inc (A1 Lithium) is pleased to announce that successful completion of the pilot program with KOCH Technology Solutions ("KTS"). The program successfully delivered all technical requirements, producing high concentration and high purity lithium chloride eluate at the onsite Direct Lithium Extraction ("DLE") unit from freshly extracted lithium rich brine at its Green River Lithium Project, in south-eastern Utah, USA.The KTS DLE Process achieved an average lithium recovery rate of 98% and the rejection rates of contaminants exceeded 99%. In addition the Li:TDS averaged 0.125 significantly exceeding the industry standard Li:TDS ratio required for downstream processing of 0.08 by 57%. This will result in lower processing costs of the lithium carbonate that the company plans to produce.Based upon these results KTS will provide to Anson/A1 Lithium "process guarantees" for a commercial scale plant of 10,000 tons per annum of lithium carbonate.The KTS DLE plant successfully produced 43,500 gallons (165,000 litres) of high-quality eluate at the Green River, Utah, USA site, which is stored and now available for downstream processing.Superior Containment Rejection and RecoveryThe KTS DLE process test work achieved an average lithium recovery rate of 98% and a high rejection rate of the key impurities meeting or exceeding all targets. Where the DLE step rejects a higher percentage of impurities, the resulting lithium chloride solution, which is to become lithium carbonate electric vehicle (EV) grade of 99.95% purity, can be converted more efficiently. The level of rejection in the preliminary results, of the key impurities from the KTS DLE process during an optimized configuration and operation parameter were:Executive CommentaryAnson's Executive Chairman & CEO, Mr. Bruce Richardson commented, "These results from the KTS DLE pilot program are exceptional. The industry leading Li:TDS ratio will make a significant contribution to the financial success of the Green River Lithium Project as will the very high rates of impurity rejection. The cooperation has been truly successful. Congratulations to both the KTS and A1 Lithium teams that worked so hard on this project. Anson looks forward to further collaboration with KTS as partners in the development of the Green River Lithium Project." Mr Richardson continued, "Testing of DLE process is essential to reduce commercial production risks and assists in financing a project. Anson has conducted several DLE test work programs, at different times of the year and the KTS results are a standout, not only technically but also from a cost perspective. Anson will continue to focus on these two aspects during the development of the Green River Lithium Project to maximize investor and shareholder returns."Lithium Business Leader at Koch Technology Solutions, Garrett Krall said, "We are proud to achieve this level of brine production at an industry-leading TDS, demonstrating the capability of Li-Pro™ technology and its continued successful commercialization with Anson. This milestone marks a great step forward for the commercial success of DLE, and we are excited to continue supporting this Project in Utah."Pathway to CommercializationKTS has indicated to Anson that there is enough data from the test work to provide a "Technical Annex" that will include process guarantees for a 10,000 tpa production plant using its Li-Pro™ LSS technology. This is expected to be completed in a few months. A process guarantee is a key requirement in securing debt funding for the Project.Exceptional Lithium Purity & Process EfficiencyThe process achieved an average lithium recovery of 98% over the seven months of operation and generated approximately 43,500 gallons (165,000 liters) of lithium chloride at or above the specifications required by downstream processors. The eluate can now be refined and concentrated using tested and proven steps to battery grade product. The production and retention of eluate provides sufficient lithium chloride for downstream test work and final product trials.DLE systems that produce a lithium chloride solution with a lithium-to-total dissolved solids ratio (Li:TDS) greater than 0.08 are considered as suitable for downstream processing. The lithium chloride eluate produced with the KTS DLE plant achieved a Li:TDS of up to 0.129. The average Li:TDS of 0.126 achieved over the program, is a 57% improvement relative to the target Li:TDS ratio of 0.08.A high Li:TDS ratio has positive implications for the costs of the lithium purification process step. A higher ratio equates to a lower amount of water to be removed (evaporated) prior to lithium carbonate precipitation. Less evaporation requires less energy to reduce the volume of eluate and increase the concentration of lithium prior to carbonation.The brine samples were assayed on site at Green River with the Company's ICP machine due to allow for continuous sampling and quick turnaround of assay results required to continually fine tune the DLE process. These assay results were then confirmed by independent third-party off-site laboratories.During the seven-month continuous operating period (August 2024 to February 2025) onsite, the KTS DLE plant successfully produced 43,500 gallons (165,000 litres) of high-quality eluate at Green River.The seven months of DLE test work allowed Anson and KTS to fine-tune the process control steps, identifying the optimal balance for lithium recovery, impurity removal, water usage, and lithium concentration under various climate conditions, including temperatures below freezing. This critical data will support the operation of the production plant, ensuring its efficiency throughout the year in diverse environmental conditions.Downstream of the DLE process, the LiCl solution which can be efficiently purified via standard ion exchange (IX) resins will be processed by various technologies to further remove the low concentrations of the unwanted impurities (e.g. calcium, potassium, magnesium, and boron). The pilot plant has shown a proven ability to produce LiCl solutions suitable as feedstock for this purification process.This announcement has been authorized for release by the Executive Chairman and CEO and reviewed & contributed to by KOCH Technology Solutions (KTS).About Anson Resources LtdAnson Resources (ASX:ASN) is an ASX-listed mineral resources company with a portfolio of minerals projects in key demand-driven commodities. Its core assets are the Green River and Paradox Lithium Project in Utah, in the USA. Anson is focused on developing these assets into a significant lithium producing operations. The Company's goal is to create long-term shareholder value through the discovery, acquisition and development of natural resources to meet the demand of tomorrow's new energy and technology markets.For further information please contact:Bruce RichardsonExecutive Chairman and CEOE: Info@AnsonResources.comWill MazeHead of Investor RelationsE: Investors@AnsonResources.comPh: +1 949-508-7834www.AnsonResources.comFollow us on Twitter @Anson_irSubscribe to Anson Resources News: Click HereSOURCE: Anson Resources Copyright 2025 ACN Newswire via SeaPRwire.com.

HONG KONG, Mar 25, 2025 - (ACN Newswire via SeaPRwire.com) - Cornerstone Technologies Holdings Limited (“Cornerstone Technolgies” or the “Group”; Stock code: 8391), a leading electric vehicle (EV) charging solutions provider in Hong Kong, today announced its audited annual results for the year ended 31 December 2024 (the “Reporting Year”).The Group achieved significant growth in the Reporting Year, with revenue nearly doubling to HK$153.1 million from HK$78.1 million in 2023. Gross profit surged by 91.8% year-on-year to HK$27.3 million. While the adjusted loss before interest, depreciation, and amortization (“Adjusted LBITDA”) further narrowed to HK$41.2 million, reflecting an improved operational efficiency and cost management.Robust Growth Across Core Businesses and Strong Market PotentialCornerstone Technologies’ core businesses – its private residential EV charging subscription service (Cornerstone HOME) and its public charging network (Cornerstone GO) – both demonstrated strong growth.  The number of Cornerstone HOME subscribers has seen significant growth, surpassing 860 households, representing a 169.6% year-on-year increase in subscriptions. The Cornerstone GO public charging network experienced remarkable growth, expanding by 436.4% year-on-year, with membership surging 165.3% to 50,498. The total number of charging sites increased from 43 to 103.  This expansion reflects the growing demand for sustainable EV charging solutions in Hong Kong. The Hong Kong Environmental Protection Department projects a 30% compound annual growth rate (CAGR) for the EV market between 2021 and 2030.  In February 2025, nearly 65% of newly registered private cars were electric vehicles, highlighting significant market acceptance and substantial future growth potential.  However, with approximately 112,000 registered EVs and only around 10,000 public charging points, a considerable supply-demand gap exists.Successful Thailand Expansion Drives International GrowthIn 2024, Cornerstone Technologies successfully launched its “Spark” branded EV charging network in Thailand, marking a key milestone in its international expansion strategy.  This venture quickly gained traction, delivering a notable 544.4% increase in international revenue.  Thailand's EV market is experiencing rapid growth. At the end of 2024, approximately 227,500 EVs were registered, yet only about 11,500 charging points were available - an EV-to-charger ratio of 19.8, indicating significant unmet demand and substantial growth potential.  The Thai government's ambitious targets -725,000 EVs by 2026 and 2.5 million by 2040 - further underscore this potential.  Based on Hong Kong's EV-to-charger ratio of 10.8, Thailand would require at least 67,129 charging points by 2026 alone. This significant market opportunity prompted Cornerstone Technologies' strategic entry into the Thai market, enabling the company to expand its global presence and build a strong foundation for future growth by directly addressing this demand.Commentary from Mr. Vincent Yip, CEO and Executive Director of Cornerstone Technologies: “The Group is making strong progress towards profitability and is confident about its future.  We are actively pursuing growth opportunities in Hong Kong, Thailand, and other markets.  Our focus remains on driving technological innovation and service excellence, reinforcing our industry leadership.  Sustainability is central to our strategy. We are committed to expanding our intelligent and high-efficiency charging solutions to meet market demand and create long-term value for our stakeholders. We believe that through continuous innovation and strategic planning, Cornerstone Technologies will play a key role in shaping a greener and smarter future for the EV industry.” Copyright 2025 ACN Newswire via SeaPRwire.com.

香港, 2025年3月25日 - (亞太商訊 via SeaPRwire.com) - 香港領先的電動車（EV）充電解決方案供應商基石科技控股有限公司（「基石科技」或「集團」；股份代號 8391.HK），今天公佈其截至2024年12月31日止年度（「報告年度」）的經審核全年業績。於報告年度內，集團業績取得了顯著的增長，收入由去年的7,810萬港元增長近一倍至1億5,310萬港元。毛利同比增長91.8%至2,730萬港元。此外，經調整之扣除利息、折舊及攤銷前虧損（「經調整LBITDA」）亦進一步收窄至4,120萬港元，體現了運營效率和成本管理方面的持續優化。核心業務強勁增長 市場增長潛力優厚基石科技核心業務 - 私人住宅EV充電訂閱服務（Cornerstone HOME）及公共充電網絡（Cornerstone GO）均展現強勁增長勢頭。其中，Cornerstone HOME訂戶數量大幅增長，突破860戶，業務按年增長達169.6%；而公共充電網絡業務Cornerstone Go更錄得436.4%的顯著按年增長，會員則按年大增165.3%至50,498名，站點總數亦由去年的43個增至103個。業務擴張充分反映本港市場對可持續充電解決方案的需求持續攀升。香港環境保護署預計香港EV市場於2021年至2030年間的複合年增長率將達30%。於2025年二月，本港新登記的私家車中，接近六成半為電動車，反映市場對EV的接受程度極高，且未來增長潛力龐大。然而，目前全港登記的EV總數已達112,000輛，而公共電動車充電設備僅約10,000個，供需之間仍存在顯著差距。成功進軍泰國市場 推動國際業務增長基石科技於2024年成功拓展至泰國市場，並以Spark品牌正式營運，在該國建立電動車充電站網絡，標誌著集團國際擴展策略的重要里程碑。泰國業務迅速獲得市場認可，更帶動國際收入錄得544.4%的顯著增幅。泰國電動車市場正處於快速增長階段，截至2024年底，該國已登記EV約為227,500輛，但可用充電設備僅有約11,500個充電點，EV與充電器的比例高達19.8，反映出顯著的需求與發展空間。泰國政府更訂下目標，計劃於2026年將EV數量提升至725,000輛，並於2040年達到250萬輛，進一步凸顯市場潛力。參考香港EV與充電器比例10.8的標準，泰國到2026年至少需要67,129個充電點。這巨大的市場機遇促使基石科技戰略性進軍泰國市場，擴展其全球佈局，為未來業務擴展奠定堅實基礎。基石科技行政總裁兼執行董事葉兆康先生表示：「集團正穩步邁向盈利，並對未來發展充滿信心。我們將積極把握香港、泰國及其他市場的發展機遇，專注於推動技術創新與提供優質服務，鞏固行業領導地位。可持續發展為我們戰略的核心 - 我們致力於拓展智能化及高效能的充電解決方案，以滿足市場需求，為持份者創造長遠價值。我們相信，透過不斷創新與戰略佈局，基石科技將在行業中扮演關鍵角色，攜邁向更綠色、更智能的未來。」 Copyright 2025 亞太商訊 via SeaPRwire.com.

香港, 2025年3月24日 - (亞太商訊 via SeaPRwire.com) - 泛遠國際控股集團有限公司（上市編號：2516，下稱「泛遠國際」；連同其附屬公司，統稱「泛遠國際」或「本集團」）欣然宣佈，本集團間接全資附屬公司杭州泛遠國際物流有限公司（「杭州泛遠」）近日成功加入亞馬遜服務商網絡（「亞馬遜SPN」），為亞馬遜平台賣家提供跨境物流服務。這不僅標誌着本集團綜合能力與服務品質得到全球電商巨頭亞馬遜的認可，同時亦有力推動本集團之跨境電商全球化佈局進程，為集團跨境物流業務的可持續發展奠定堅實基礎。亞馬遜SPN是亞馬遜針對賣家尋找服務商難、同類服務商難對比、溝通週期長等痛點，推出的「一站式跨境解決方案」工具，能幫助賣家快速找到合適的服務商並建立聯繫。其涵蓋包括物流、海外倉、合規稅務在內的8大服務板塊，提供逾30種服務類型，並覆蓋19大亞馬遜海外站點，高效連接賣家與服務商，最終協助賣家達成跨境出海之目標。選定為亞馬遜SPN需經過多維度、嚴苛的資質審核，對認證服務商的服務能力、運營效率、客戶口碑、合規性及品牌影響力均有高標準的要求。泛遠國際作為中國知名的跨境電商物流服務商，擁有廣泛的服務網點及供應商網絡，可為客戶提供多項靈活可靠的跨境配送選項，並在市場上積累良好口碑。是次本集團附屬成功通過亞馬遜各項嚴苛審核，最終成為亞馬遜SPN的認證服務商。這不僅是亞馬遜平台對本集團跨境電商服務能力和卓越運營管理水平的高度認可，更為本集團深化全球佈局注入強勁動力。本集團將透過亞馬遜SPN平台積極開拓海外市場，與全球范圍內的新興客戶建立深度合作關係，並致力於以穩、快、優的跨境物流綜合服務體系，滿足不同國家和地區客戶的多樣化需求，為更多企業順利出海保駕護航。泛遠國際控股集團有限公司主席兼執行董事王泉先生表示：「今次有集團附屬公司成功加入亞馬遜服務商網絡，我們既驚喜又榮幸。這是繼阿里巴巴國際站後，又一全球知名跨境電商平台對本集團於跨境物流領域多年深耕與卓越能力的充分肯定。此次成為亞馬遜服務商有望為本集團帶來更多優質客戶資源與業務機會，同時亦將進一步深化本集團在跨境電商的全球化佈局。展望未來，本集團將積極把握市場機遇，深度整合物流網絡資源，持續為客戶提供更高效便捷的跨境物流服務。同時，本集團亦將繼續深化大平台戰略合作，重點拓展與主流跨境電商平台的深度合作，進一步拓展中小直客，助力更多企業出海。」有關泛遠國際控股集團有限公司（股份代號：2516.HK）泛遠國際控股集團有限公司於2023年12月在香港聯交所主板掛牌上市，為中國知名的跨境電子商務物流服務供應商，主要提供端到端跨境配送服務、貨運代理服務以及其他物流服務，致力打造穩、快、優的跨境電子商務物流服務體系。本集團作為中國（杭州）跨境電子商務綜合試驗區首批試點企業，擁有創新的自研物流運輸系統，採用直營網點模式，網點遍佈中國主要貿易中心，尤其聚焦於長江三角洲及粵港澳大灣區。本集團設有30多個境內網點，1,100多家供應商網路，服務覆蓋全球超過220多個國家和地區，向客戶提供多項靈活可靠的跨境配送選項及定制化供應鏈解決方案。有關杭州泛遠國際物流有限公司杭州泛遠國際物流有限公司為本集團全資附屬公司，主營國際海運、國際空運、國際快件代理業務、跨境電子商務供應鏈及全球物流倉儲整體解決方案等服務。公司秉承「以人為本，傾力親為」的宗旨，致力於打造以涵蓋國際貨物運輸所有業務門類的操作平台為核心的，集倉儲、分撥、配送、物流方案解決為一體的，以跨境物流和全球倉儲服務為基礎的一站式集成物流解決方案供應商。 Copyright 2025 亞太商訊 via SeaPRwire.com.

香港, 2025年3月24日 - (亞太商訊 via SeaPRwire.com) - 紙製品製造及印刷服務供應商雋思集團控股有限公司（「雋思集團」或「集團」；股份代號：1412），今日公布其截至2024年12月31日止年度（「2024年財政年度」或「報告期內」）之全年業績。於2024年財政年度，受惠於原始設備製造商（「OEM」）及網站銷售客戶的需求增加，集團總收益約為1,210.9百萬港元，較去年同比增加約16.5%，加上營運及生產效率持續提升，本公司權益股東應佔溢利大幅上升約61.2%至約129.1百萬港元。董事會建議派發2024年財政年度期末股息每股11.0港仙（2023年財政年度：8.0港仙）。連同已支付之中期股息3.0港仙（2023年財政年度：2.0港仙），2024年財政年度的股息總額將為每股14.0港仙（2023年財政年度：10.0港仙）。業務回顧於報告期內，集團堅定專注於穩步擴張業務和優化營運，成功把握主要OEM客戶產品需求增加帶來的新商機。此外，集團在不同產品線的業務多元化方面取得穩步進展。憑藉在集換式卡牌的產品開發、生產技術及營運標準等方面的優勢，集團與全球集換式卡牌的領先企業及一眾內地集換式卡牌發行商建立業務關係。於報告期內，集團的OEM銷售約984.8百萬港元，較2023年財政年度的約845.8百萬港元增加約16.4%。網站銷售業務方面，憑著穩固的市場地位、優良的客戶體驗及有效的節約成本措施，集團的網站銷售於報告期內取得穩步增長。集團近年推出的企業對企業對消費者(B2B2C)電商平台Q P Market Network (「QPMN」)亦持續提升網站基礎設施及功能，並成功與全球多個業務夥伴建立業務關係。於2024年財政年度，集團的網站銷售約226.1百萬港元，較2023年財政年度的約193.4百萬港元增加約16.9%。營運方面，越南廠房於報告期內全面投入運作，成為集團重要的生產點。於2024年9月，集團就越南工廠擴建的建設工程，與承建商訂立建造協議。展望展望未來，集團會繼續專注於業務的穩步擴張及優化營運，透過產品結構設計、印刷及加工技術及物料使用方面的創新，進一步加強其OEM方案。有見集換式卡牌遊戲市場蓬勃發展，集團將積極參與相關貿易展會，促進在相關市場的發展，把握當中機遇。發展QPMN仍為集團網站銷售業務中重要的長遠增長策略。集團將擴闊其產品種類，加強其與市場上普及的電商平台的整合，使其產品定製電商方案更貼合市場標準和業務夥伴的期望。自有品牌生產(「OBM」)業務方面，品牌團隊已制訂一連串線上和線下策略，旨在開拓更多銷售渠道，擴大市場份額和客戶基礎。除卡牌外，品牌將研究集換式卡牌遊戲、桌遊、塔羅牌等其他產品的市場潛力，以提升品牌知名度及拓闊收入來源。集團將繼續優化生產營運。越南生產基地的擴建工程進展順利，並預期於2025年第三季度投產。此策略性擴充將有助集團在越南建立更全面的供應鏈，分散地緣政治因素引起的潛在營運風險。另一方面，隨著新近達成工業4.0 2i成熟度認證的里程碑，集團將致力改善營運數據的使用，並把智能運作的應用擴展至更多生產線及車間，以推動數碼轉型。雋思集團創始人、主席及行政總裁鄭穩偉先生總結：「2025年，製造業預期將面對機遇與挑戰並存的複雜經濟格局。消費市場在經濟穩步增長及通脹緩和的支撐下預料將展現韌性，而全球地緣政治局勢緊張觸發關稅的實施及保護主義的加劇，無可避免會對製造業造成影響。基於我們穩固的業務及財務基礎，我們對集團的長期前景抱有信心。我們將持續執行合適的策略，務求保持穩定成長並為持份者創造長期價值。」有關雋思集團控股有限公司（股份代號：1412）雋思集團於1985年在香港成立，是中國領先的紙質桌遊及賀卡生產商之一。生產基地位於廣東省東莞市、鶴山市以及越南河南省府里市。主要產品類別為桌遊、賀卡、集換式卡牌、幼教用品及包裝彩盒。集團自2010年開始經營網上客製化產品訂製業務，提供多元化紙製品及禮品訂製方案，現時活躍註冊用戶數量超過77,600個。隽思集团主要网站：www.makeplayingcards.comwww.boardgamesmaker.comwww.createjigsawpuzzles.comwww.printerstudio.comQ P Market Network：www.qpmarketnetwork.com如欲索取隽思集团更多资料，请浏览网址：https://www.qpp.com/tc/傳媒查詢縱橫財經公關顧問有限公司李惠兒電話：（852）2864 4834電郵：vicky.lee@sprg.com.hk梁家儀電話：（852）2114 4172電郵：phoebe.leung@sprg.com.hk程梓豪電話：（852）2864 4894電郵：will.cheng@sprg.com.hk網址: http://www.sprg.com.hk  Copyright 2025 亞太商訊 via SeaPRwire.com.

Brisbane, Queensland, Australia--(ACN Newswire via SeaPRwire.com - March 20, 2025) - Graphene Manufacturing Group Ltd. (TSXV: GMG) ("GMG" or the "Company") is pleased to announce that it has completed its previously announced bought deal offering of 7,245,000 units (the "Units") at a price of C$0.80 per Unit (the "Offering Price") for aggregate gross proceeds to the Company of C$5,796,000, which includes the exercise in full of the Underwriters' (as defined below) over-allotment option for 945,000 Units (the "Offering").Each Unit will consist of one common share of the Company (each, a "Unit Share") and one common share purchase warrant (each a "Warrant"). Each Warrant shall be exercisable into one additional common share of the Company for a period of 36 months from the closing of the Offering at an exercise price of C$1.10.Under the Offering, Ventum Financial Corp. acted as lead underwriter and sole bookrunner on behalf of a syndicate of underwriters including Red Cloud Securities Inc. (the "Underwriters") pursuant to the underwriting agreement entered into between the Underwriters and the Company dated March 14, 2025.The Offering was completed pursuant to a prospectus supplement dated March 14, 2025 to the short form base shelf prospectus of the Company dated March 7, 2025 in each of the provinces of Canada (except Quebec), in the United States on a private placement basis pursuant to an exemption from the registration requirements of the U.S. Securities Act of 1933, as amended (the "U.S. Securities Act") and applicable state securities laws and other jurisdictions outside of Canada and the United States on an exempt basis, provided that the issuance of the Units (including the underlying securities) is permitted under laws applicable to the Company (including the Australian Corporations Act 2001 (Cth). The Offering remains subject to the final approval of the TSX Venture Exchange.The Company intends to use the net proceeds of the Offering to expand its production capacity to increase sales, continue ongoing research and development to progress the Graphene Aluminium-Ion Battery with the Battery Innovation Center of Indiana, prepare to uplist on a major United States exchange and working capital and general corporate purposes.In connection with the Offering, the Company paid the Underwriter a cash commission equal to 7% of the gross proceeds of the Offering and issued to the Underwriter such number of compensation warrants as is equal to 7% of the number of Units sold pursuant to the Offering (the "Compensation Warrants"). Each Compensation Warrant is exercisable into a Unit Share at the Offering Price until 36 months from the closing of the Offering.This news release does not constitute an offer to sell or a solicitation of an offer to sell any of securities in the United States. The securities have not been and will not be registered under the U.S. Securities Act or any state securities laws and may not be offered or sold within the United States or to U.S. persons as defined under Regulation S, unless registered under the U.S. Securities Act and applicable state securities laws or an exemption from such registration is available.About GMG:GMG is an Australian based clean-technology company which develops, makes and sells energy saving and energy storage solutions, enabled by graphene manufactured via in house production process. GMG uses its own proprietary production process to decompose natural gas (i.e. methane) into its natural elements, carbon (as graphene), hydrogen and some residual hydrocarbon gases. This process produces high quality, low cost, scalable, 'tuneable' and low/no contaminant graphene suitable for use in clean-technology and other applications.The Company's present focus is to de-risk and develop commercial scale-up capabilities, and secure market applications. In the energy savings segment, GMG has initially focused on graphene enhanced heating, ventilation and air conditioning ("HVAC-R") coating (or energy-saving coating) which is now being marketed into other applications including electronic heat sinks, industrial process plants and data centres. Another product GMG has developed is the graphene lubricant additive focused on saving liquid fuels initially for diesel engines.In the energy storage segment, GMG and the University of Queensland are working collaboratively with financial support from the Australian Government to progress R&D and commercialization of graphene aluminium-ion batteries ("G+AI Batteries"). GMG has also developed a graphene additive slurry that is aimed to improve the performance of lithium-ion batteries.GMG's 4 critical business objectives are:Produce Graphene and improve/scale cell production processesBuild Revenue from Energy Savings ProductsDevelop Next-Generation BatteryDevelop Supply Chain, Partners & Project Execution CapabilityFor further information please contact:Craig Nicol, Chief Executive Officer & Managing Director of the Company at craig.nicol@graphenemg.com, +61 415 445 223Leo Karabelas at Focus Communications Investor Relations, leo@fcir.ca, +1 647 689 6041Cautionary Note Regarding Forward-Looking StatementsThis news release includes certain statements and information that may constitute forward-looking information within the meaning of applicable Canadian securities laws. Forward-looking statements relate to future events or future performance and reflect the expectations or beliefs of management of the Company regarding future events. Generally, forward-looking statements and information can be identified by the use of forward-looking terminology such as "intends", "expects" or "anticipates", or variations of such words and phrases or statements that certain actions, events or results "may", "could", "should", "would" or will "potentially" or "likely" occur. This information and these statements, referred to herein as "forward‐looking statements", are not historical facts, are made as of the date of this news release and include without limitation, the business objectives, focus and strategy of the Company; ongoing R&D of the Company; the anticipated use of proceeds of the Offering; the receipt of all necessary approvals, including the final approval of the TSX Venture Exchange.Such forward-looking statements are based on a number of assumptions of management, including, without limitation, expectations and assumptions concerning the business objectives of the Company; the Company's ability to carry out current planned capital projects, research and development, manufacturing, production, sales and marketing programs for its graphene and graphene-enhanced products and solutions; receipt of all necessary approvals the Company's ability to list Common Shares on the TSX Venture Exchange; the Company's performance and general business and economic conditions. Additionally, forward-looking information involves a variety of known and unknown risks, uncertainties and other factors which may cause the actual plans, intentions, activities, results, performance or achievements of GMG to be materially different from any future plans, intentions, activities, results, performance or achievements expressed or implied by such forward-looking statements. Such risks include, without limitation: overall economic conditions, technical de-risking and market acceptance for the Company's products and solutions; the introduction of competing technologies or products; stock market volatility; environmental and regulatory requirements; competitive pressures; change in market conditions and other factors that may cause the actual results, performance or achievements of the Company to differ materially from those expressed or implied in these forward looking statements; risks relating to the extent and duration of the conflict in Eastern Europe and the Middle East and its impact on global markets, the volatility of global capital markets, political instability, the failure of the Company to obtain regulatory approvals, attract and retain skilled personnel, unexpected development and production challenges, unanticipated costs and the risk factors set out under the heading "Risk Factors" in the Company's annual information form dated October 3, 2024 available for review on the Company's profile at www.sedarplus.ca.Although management of the Company has attempted to identify important factors that could cause actual results to differ materially from those contained in forward-looking statements or forward-looking information, there may be other factors that cause results not to be as anticipated, estimated or intended. There can be no assurance that such statements will prove to be accurate, as actual results and future events could differ materially from those anticipated in such statements. Accordingly, readers should not place undue reliance on forward-looking statements and forward-looking information. Readers are cautioned that reliance on such information may not be appropriate for other purposes. The Company does not undertake to update any forward-looking statement, forward-looking information or financial out-look that are incorporated by reference herein, except in accordance with applicable securities laws.NOT FOR DISTRIBUTION TO THE U.S. NEWSWIRE OR FOR DISSEMINATION IN THE UNITED STATESTo view the source version of this press release, please visit https://www.newsfilecorp.com/release/245420 Copyright 2025 ACN Newswire via SeaPRwire.com.

MANILA, March 20, 2025 - (ACN Newswire via SeaPRwire.com) - Union Bank of the Philippines (PHS: UBP) has been awarded with the Best Wealth Management Bank in the Philippines, at the 2025 Global Excellence in Retail Finance Awards, held in February by The Asian Banker. A testament to its strategic vision, innovative wealth solutions, and unwavering commitment to financial excellence, this accolade underscores UnionBank’s success in redefining the wealth management landscape through digital innovation, strategic acquisitions, and customer-centric investment solutions.Setting a New Benchmark in Wealth Management“UnionBank has strengthened its affluent banking proposition by seamlessly integrating the acquired Citi wealth business, further enhancing its ability to serve a diverse spectrum of wealth clients. From emerging affluent individuals to high-net-worth investors, the bank has introduced a transformative approach to wealth management, providing tailored solutions that cater to clients’ evolving financial needs,” read The Asian Banker’s citation at the Awards, held this year in Tokyo, Japan.“For its successful integration of acquired expertise, relentless commitment to financial innovation, and dedication to delivering sophisticated wealth solutions, UnionBank is honored with the title of Best Wealth Management Bank in the Philippines. This recognition reflects the bank’s mission to empower Filipinos in achieving their financial goals through world-class wealth management services.”Introducing Elite and Access: A New Era in Wealth SolutionsA key milestone in UnionBank’s wealth management evolution is the launc of Elite and Access, two pioneering programs designed to provide tiered wealth solutions: * Access is tailored for emerging affluent clients, offering seamless digital wealth tools and an extensive suite of investment products.  * Elite is designed for high-net-worth investors, delivering bespoke financial planning, exclusive global investment opportunities, and dedicated relationship management.These programs redefine financial accessibility and personalization, ensuring that clients receive the right level of support, expertise, and product offerings based on their financial standing and aspirations.“We thank The Asian Banker for recognizing our unwavering commitment to excellence, innovation, and, most importantly, our clients. At UnionBank wealth management is about building trust, securing futures, and creating opportunities.” said   UnionBank Wealth and Brokerage Head and Board Director of UB Financial Services and Insurance Brokerage Inc. (UFSI), Therese Chan.“The strategies we craft and solution we provide are driven by our dedication to helping our clients achieve their financial goals. We remain committed to setting new standards in wealth management and empowering more people to build a stronger financial future.” continued Ms Chan.UnionBank’s ability to serve a diverse spectrum of wealth clients is further bolstered by its world-class Wealth Center, which was unveiled to the media on the same day it received the prestigious Asian Banker Award.Digital Innovation Meets Global Investment AccessUnionBank continues to lead the industry with its enhanced digital wealth platform, allowing clients to diversify their portfolios with global investment products—without the need for offshore accounts. This innovation ensures that clients can securely access a world of investment opportunities from the convenience of a seamless, digital-first banking experience.By blending cutting-edge technology with highly personalized advisory services, UnionBank has solidified its position as the preferred financial partner for wealth clients across the Philippines. The bank’s dedication to innovation, accessibility, and global investment integration has set a new gold standard in the country’s wealth management sector.As UnionBank continues to drive financial excellence and innovation, it remains steadfast in its vision to elevate wealth management in the Philippines—paving the way for a smarter, more inclusive financial future to help clients build, grow, and protect their wealth.To learn more about UnionBank Elite, visit www.unionbankph.com/wealth/elite or email ubwealth@unionbankph.com. Copyright 2025 ACN Newswire via SeaPRwire.com.

- FILMART and EntertainmentPulse drew industry players from 42 countries and regions, attracting more than 7,600 global participants, promoting cross-regional, cross-media and cross-industry collaboration and strengthening Hong Kong’s position as a centre for cultural and artistic exchange- There was significant growth of ASEAN exhibitors and buyers with over 50% and 15% increase respectively year-on-year- The inaugural Producers Connect programme, jointly organised by the Culture, Sports and Tourism Bureau, Creative Industries Development Agency, the Hong Kong Film Development Council, and Hong Kong Trade Development Council received an overwhelming response, drawing more than 1,300 participants to discuss the collaboration opportunities across various markets- AI applications and Asian animation took centre stage, bringing together industry experts to explore the synergy between innovative technology and creative industriesHONG KONG, Mar 20, 2025 - (ACN Newswire via SeaPRwire.com) - Organised by the Hong Kong Trade Development Council (HKTDC), Hong Kong International Film & TV Market (FILMART) and EntertainmentPulse drew to a successful close today, attracting more than 7,600 industry players from 42 countries and regions, promoting cross-regional, cross-media and cross-industry collaboration. The four-day event brought together more than 760 exhibitors from 34 countries and regions. The event was more international this year, with particularly strong growth in participation from ASEAN countries which saw exhibitor numbers surge by more than 50% while buyer attendance from the region rose 15% year-on-year.Producers Connect opens new avenues for global film collaborationThe inaugural Producers Connect programme, jointly organised by the Culture, Sports and Tourism Bureau, Creative Industries Development Agency (CCIDA), the Hong Kong Film Development Council, and HKTDC received an overwhelming response. The initiative attracted strong participation from international producers alongside veteran and emerging local filmmakers, including Oliver Chan, Tenky Tin, Jill Leung, drawing more than 1,300 participants to discuss the collaboration opportunities across various markets. A highlight of the programme, “International Coproduction: Balancing Risk and Rewards”, explored crucial aspects of creative talent integration, funding sources diversification and audience base expansion.Industry leaders including Gabriela Tocchio, Executive Producer of Gullane Films from Brazil, Justin Kim, Head of International Film Production at Korea's CJ ENM, and Natacha Devillers, Producer at France's Les Petites Lumières, shared insights on overcoming cultural differences and logistical challenges.The programme featured a "Fireside Chats" series focusing on global market development strategies, emerging and European market opportunities, and intellectual property (IP) development and extension, providing local producers with valuable international perspectives while fostering cross-regional partnerships.Additionally, at the EntertainmentPulse forum, veteran film critic Thomas Shin, The Last Dance’s director and producer Anselm Chan, screenwriter Cheng Wai-kei, alongside Papa’s producer Amy Chin and director-screenwriter Philip Yung, discussed the transformation and prospects of Hong Kong cinema.Growing international presence connects global industry playersThis year's FILMART featured various regional pavilions with distinctive programmes to showcase their thriving film, television and entertainment industries to global participants - Thailand's Ministry of Culture hosted two forums highlighting its creative cultural industry capabilities; Indonesia themed its participation around fostering global partnerships, presenting diverse works; while the National Film Development Corporation Malaysia (FINAS)  focused on Asia collaboration this year, Dato' Azmir Saifuddin Bin Mutalib, CEO, National Film Development Corporation Malaysia (FINAS) said, “It was a great start on the first day of FILMART 2025, and among the discussions that concluded successfully is the discussion with the HK Cultural & Creative Development Agency on co-production funding, finalising an MoU with KOFIC Korea and discussion with Cambodia on market access.”The Investment New South Wales (NSW) of Australia made its debut appearance at FILMART, promoting local creative industry development, Helen Sawczak, NSW Senior Trade and Investment Commissioner, Greater China said, “We are excited to be making our debut at FILMART and eager to connect world-class screen industry with global partners. As one of the premier international forums for film and entertainment, FILMART offers the ideal stage to showcase NSW’s creative excellence while fostering cross-border collaborations and opportunities.”First-time participants including Armenia, the Czech Republic, and Kazakhstan, and, along with buyers from emerging markets such as Argentina, Bulgaria, Kyrgyzstan and Pakistan, underscore Hong Kong's crucial role as a bridge connecting global film and television markets.AI expands production horizons with Ne Zha 2 team sharing success storyThe exhibition's spotlight feature, the pilot project AI Hub, brought together ten exhibitors showcasing innovative AI solutions spanning across production, post-production, distribution, and promotional applications, attracting more than 3,900 industry professionals to take part in its interactive forums at the exhibition zone. Riding on the global success of Ne Zha 2, EntertainmentPulse hosted a forum titled “Gearing up for the AI Opportunities”, featuring special presentations from Hong Li Animation Studios and Heguang Post-Production, who shared their experiences in AI-powered special effects creation. Liu Baoyu, Vice General Manager of Heguang Post-Production, said "We should make good use of AI while maintaining respect for traditional art, as we continue to explore new forms of artistic expression." Jihong Chen, Partner of Zhong Lun Law Firm emphasised that AI proficiency is now crucial for staying competitive.Key events highlight industry developments and Asian animation's new opportunitiesThe Digital Entertainment Summit was themed as “Unlock Opportunities of the Dynamic Animation Market and Productions in Asia” and was jointly organised by the Hong Kong International Film Festival Society and Hong Kong Digital Entertainment Association. The summit featured two specialist panels namely "Asian Animation Market Trends & Development" with speakers including Catherine Ying, Vice President of CMC Inc. and President of Pearl Studio; Francesco Prandoni, Global Licensing Team Leader at Production I.G, Inc. and Mia Angelia Santosa, Chief of Staff at Visinema; and Kang Yue, Senior Business Director at bilibili, who shared insights on market opportunities.The second panel, "Prospects for Asian Animation Creation & Production in Asia", featured Karyabudi Mohd. Aris, Director of Marketing, Sales and Licensing at Les' Copaque Production Sdn., Nao Hirasawa, CEO of ARCH Inc., Polly Yeung, Producer and Scriptwriter at Point Five Creations, and Yu Zhou, Co-founder and President of Light Chaser Animation Studios, who explored the latest developments in Asian animation production.Phoenix TV and the UK Department for Business and Trade also jointly held a UK-China Screen Forum during FILMART and announced that the BBC Studio documentary "Asia" and the iconic IP "Walking with Dinosaurs" will be exclusively screened on Phoenix TV Chinese Channel and iQiyi respectively, further promoting UK-China film and television cooperation.The 23rd Hong Kong - Asia Film Financing Forum (HAF23) was also held during FILMART, where 48 selected film projects participated in business matching sessions with investors, producers, and distributors from over 35 countries and regions during the three-day event, further exploring investment opportunities for the Asian film and entertainment industry.To facilitate industry exchange and rights trading, FILMART also featured 24 screenings including 10 world premieres, 7 international premieres, and 5 Asian premieres, alongside pitching sessions and business matching activities.This year, the Hong Kong Entertainment Expo introduced the new "Hong Kong Film Music Fiesta," organised by the Hong Kong Film Composers' Association. Under the theme "Echoes of Order and Chaos" and led by music directors Tomy Wai and Julian Chan, the showcase performed classic selections from various film composers, paying tribute to acclaimed filmmakers and musicians including Benny Chan, Teddy Robin, and Kenji Kawai, while exploring the timeless duality of justice and crime through action themes, showcasing the distinctive flair and creative excellence of Hong Kong film music.Additionally, there were three flash-mob performances all with a Hong Kong movie music theme, to demonstrate the distinctive appeal of cross-media collaboration between music and film, fostering more cross-sector partnerships.All registered attendees at FILMART can access the online IP catalogue which features over 1,600 creative IP projects, extending the four-day physical exhibition into a two-month networking platform, assisting the industry explore business opportunities and further strengthening Hong Kong's position as Asia's film and entertainment trading hub. The catalogue will remain accessible until 27 April 2025, enabling the industry to continue exploring global business opportunities.Website:     FILMART-www.hktdc.com/hkfilmart/enEntertainmentPulse-entertainmentpulse.hktdc.com/enPhoto Download:https://bit.ly/4bKZLCCFILMART and EntertainmentPulse, organised by the Hong Kong Trade Development Council, attracted more than 7,600 industry professionals from 42 countries and regions, showcasing Hong Kong's position as Asia's leading entertainment hub.EntertainmentPulse featured numerous industry leaders as keynote speakers in various forums, exploring topics including cross-border co-production, ASEAN markets, Asian animation industry, and streaming media trends.This year's FILMART further strengthened its international profile and hosted more than 30 pavilions. Among them, the National Film Development Corporation of Malaysia (FINAS) signed several co-operation agreements.The inaugural "Hong Kong Movie Music Showcase", produced by the Hong Kong Film Composers' Association, presented three flash-mob performances during FILMART. Under the artistic direction of Tomy Wai and Julian Chan, the ensemble delivered a masterful repertoire of classic Hong Kong film scores, unified by the theme "Echoes of Order and Chaos"FILMART's global platform provided a unique and world renowned venue for film and entertainment companies and organisations to unveil their forthcoming productions and strategic initiatives to global industry players.Veteran film critic Thomas Shin, alongside The Last Dance director-producer Anselm Chan, screenwriter Cheng Wai-kei, Papa producer Amy Chin and director-screenwriter Philip Yung, engaged in a forum on the transformation and future trajectories of Hong Kong cinema.Media enquiriesFor enquiries, please contact:Raconteur PR:Betsy Tse     Tel: (852)  9742 7338           Email: betsytse@raconteur.hkMolisa Lau    Tel: (852)  6187 7786           Email: molisalau@raconteur.hkHKTDC Communication and Public Affairs Department:Kelly Shek    Tel: (852) 2584 4554            Email: kelly.yt.shek@hktdc.orgSnowy Chan    Tel: (852) 2584 4525            Email: snowy.sn.chan@hktdc.orgHKTDC Newsroom: http://mediaroom.hktdc.com/enAbout the HKTDCThe Hong Kong Trade Development Council (HKTDC) is a statutory body established in 1966 to promote, assist and develop Hong Kong ’s trade. With 50 offices globally, including 13 in Mainland China, the HKTDC promotes Hong Kong as a two-way global investment and business hub. The HKTDC organises international exhibitions, conferences and business missions to create business opportunities for companies, particularly SMEs, in the mainland and international markets. The HKTDC also provides up-to-date market insights and product information via trade publications, research reports and digital news channels. For more information, please visit: www.hktdc.com/aboutus. Copyright 2025 ACN Newswire via SeaPRwire.com.

SINGAPORE, Mar 24, 2025 - (ACN Newswire via SeaPRwire.com) - The Korea Agro-Fisheries and Food Trade Corporation (aT) continues to champion the excellence of Korean produce in Singapore with its latest showcase — an exclusive event celebrating premium Korean rice and fruits. The event, held yesterday at The Butcher’s Dining, featured a live cooking demonstration and tasting session, offering attendees a firsthand experience of Korea’s finest agricultural products. The event was graced by the presence of Song Mi-Ryung, the Minister of Agriculture, Food and Rural Affairs of South Korea and Hong Jin-Wook, the Ambassador of the Republic of South Korea to Singapore.Clockwise from Top Left Image: Korean Culinary Masterclass Held at The Butcher's Dining, Minister Song Interacting with Masterclass guests, Korean Fresh Zone at CS Fresh at Great World City, Minister Song Browsing Products at the Korean Fresh ZoneSince its establishment in 1967, aT has played a pivotal role in promoting Korean food products worldwide, fostering deeper appreciation through strategic events and brand partnerships. With the growing demand for high-quality international produce in Singapore, aT aims to introduce more consumers to the unique textures, flavors, and versatility of Korean rice and fruits.Distinctive Korean FlavoursKorean cuisine is celebrated not only for its bold flavors but also for its numerous health benefits, thanks to its emphasis on fresh, nutrient-rich ingredients and time-honored culinary traditions. A cornerstone of Korean food is its use of fermented ingredients such as kimchi and doenjang (soybean paste), which are packed with probiotics that support gut health, improve digestion, and enhance overall well-being. These naturally fermented foods contribute to a balanced diet, aligning with the increasing consumer focus on digestive health and immune-boosting nutrition.Renowned for its chewy texture and exceptional quality, Korean rice has established itself as a distinctive staple in Singapore’s culinary landscape, setting it apart from varieties such as Thai jasmine rice and Vietnamese broken rice. Naturally gluten-free and rich in essential nutrients, Korean rice as well as rice products serves as the foundation for many beloved dishes, including bibimbap, tteokguk, and tteokbokki. Bibimbap stands out as a nutritionally balanced dish, featuring a vibrant medley of Korean vegetables that are high in fiber, vitamins, and antioxidants – key elements of a health-conscious diet. The focus on fresh, seasonal ingredients aligns with the growing global demand for healthier food choices, as reported by The Business Research Company, the functional foods market is projected to expand from $281.3 billion in 2024 to $315.1 billion in 2025, reflecting a robust compound annual growth rate (CAGR) of 12%.Beyond staple grains, Korean fruits such as Shine Muscat grapes and premium strawberries have gained international recognition for their exceptional sweetness and quality. Frequently used in both savory and dessert dishes, these fruits are not only a treat for the palate but also rich in antioxidants and vitamin C, further reinforcing the health benefits of Korean cuisine. As consumers worldwide increasingly prioritise immune-boosting foods, the demand for nutrient-dense Korean ingredients continues to rise.Premium K-Food Exhibition: A Display of Various Korean Rice Products as well as Other Korean ProduceAt the event, a stunning display of premium K-Food export products took center stage. From Korean rice and rice-based products to traditional liquors and premium fruits such as Korean strawberries and Shine Muscat grapes, the showcase offered a rich selection of Korea’s finest ingredients. A standout highlight was the introduction of 12 traditional Korean liquors, specially airlifted from Korea for this event. These liquors, many of which had never been exported to Singapore before, showcased the incredible diversity of Korean traditional brews, featuring unique ingredients such as plum, lingzhi, pine and yuzu, all crafted with a base of Korean rice.Adding to the excitement was the Baba Gimbap, a product that made waves after selling out in major U.S. retail stores in 2023. Visitors also had the chance to discover a variety of rice-based delicacies, including porridge, tteokbokki, and rice cakes.The fresh produce display corner was undoubtedly the centerpiece of the event. Featuring Korean-grown rice, renowned for its superior quality, alongside premium Korean strawberries and Shine Muscat grapes, the display highlighted some of Korea’s most coveted agricultural treasures. With their vibrant colors and pristine presentation, these premium ingredients created a stunning visual showcase, embodying the essence of luxury and excellence. Guests had the opportunity to explore these exquisite products up close, further deepening their appreciation for the richness of Korean fresh produce.A Culinary Showcase: Korean Ingredients in Everyday CookingThe event featured a live cooking demonstration led by esteemed culinary instructor Kim Hyuna, who guided attendees through the preparation of four signature dishes incorporating Korean ingredients, including premium rice and fruits:Bibimbap – A classic Korean mixed rice dish featuring a vibrant assortment of seasonal local and Korean vegetables and a rich, flavourful gochujang (red chili paste) sauce.Gungjung Tteokbokki – A royal court-style variation of the popular dish that showcases the diversity of tteokbokki by incorporating an assortment of vegetables. The combination of fresh ingredients and the chewy texture of tteok creates a harmonious blend of flavors.Tteokguk – Despite being a staple in Korean cuisine, tteokguk remains relatively unknown overseas. This dish is prepared by simmering beef until tender in a deeply flavourful broth and seasoned with a simple yet refined touch, tteokguk is the quintessential New Year’s dish, comforting, satisfying, and rich in cultural significance.Nurungji Ice Cream – A unique dessert crafted from nurungji (crispy scorched rice) and millet powder. Soft ice cream is paired with crunchy nurungji crackers and a dusting of warm millet powder, drawing inspiration from the Western affogato. Seasonal Korean strawberries or Shine Muscat grapes are added as toppings for a refreshing twist.Guests also had the opportunity to savour these dishes alongside traditional Korean wine pairings, enhancing their appreciation of the depth and complexity of Korean cuisine.A Commitment to Elevating Korean Produce in SingaporeSpeaking at the event, Song Mi-Ryung, Minister of Agriculture, Food and Rural Affairs of South Korea, remarked, “As we celebrate the 50th anniversary of diplomatic relations between South Korea and Singapore, we are deeply honored to host this event, showcasing the best of Korean cuisine in Singapore. We have carefully curated four special menus featuring premium Korean rice and rice products, fresh strawberries and shine muscat grapes, all grown in Korea’s distinct four seasons, paired with traditional liquors that perfectly complement each dish. We hope that many in Singapore will come to appreciate and enjoy these exceptional Korean ingredients, from rice-based delicacies to our vibrant fruits and time-honored liquors. This event reaffirms aT’s dedication to enhancing awareness and accessibility of Korean produce in Singapore. By showcasing the superior quality and versatility of Korean rice and berries, we aim to strengthen our presence in the market and inspire more consumers to embrace the rich and diverse flavors of Korea.”Korean Fresh Zone: Masterclasses and more at CS Fresh at Great World CityBuilding on the excitement around Korean fresh produce, aT, in partnership with CS Fresh at Great World City, will be hosting the Korean Fresh Zone Promotion from 20 to 26 March.Renowned chef Daren Teo – better known online as @thepantryboy – will be leading a series of exclusive masterclasses, showcasing the art of preparing iconic Korean dishes such as Japchae, Kimchi-jjigae, Boseot Jeongol and delectable Korean-inspired desserts like fruit tarts. With a background that includes training in France under a three-Michelin-starred chef and experience at the Michelin-starred restaurant Burnt Ends, Chef Daren will share expert techniques using the finest Korean fresh produce available at the Korean Fresh Zone in CS Fresh at Greeat World City, including over 40 varieties of vegetables and mushrooms, as well as premium Korean strawberries and Shine Muscat grapes. The masterclasses will be hosted by Eric Youn (@esyfilms), a beloved content creator known as the "Korean Oppa from Singapore”, attendees will get to sample some of the dishes and even stand a chance to win exclusive giveaways!Shoppers who spend $30 or more on Korean Fresh Zone produce, Korean strawberries or Shine Muscat grapes will receive a complimentary set of three chocolate-coated strawberries from chocolate boutique, BerryBar. Shoppers can choose from available designs in-store, while stocks last.Don't miss this exciting celebration of Korean flavors at CS Fresh!For more information on upcoming events and partnerships by aT, please visit www.at.or.kr.About the Korea Agro-Fisheries and Food Trade Corporation (aT)Established in 1967, the Korea Agro-Fisheries and Food Trade Corporation (aT) is a key government agency dedicated to advancing the global trade, export, and marketing of Korean foods and beverages. With a mission to elevate Korean agricultural products and culinary culture worldwide, aT leverages strategic partnerships and innovative strategies to promote Korean products while adapting to key trends, benefiting both producers and consumers. Copyright 2025 ACN Newswire via SeaPRwire.com.

TAIPING, Malaysia, Mar 24, 2025 - (ACN Newswire via SeaPRwire.com) - This Hari Raya Aidilfitri, Spritzer invites Malaysians to celebrate the heart of the season by creating new, happy memories through simple, thoughtful acts of understanding and kindness. In conjunction with the 2025 Hari Raya celebrations, from 21st March to 20th April 2025, the Spritzer EcoPark has been freshly adorned, transforming it into a festive sanctuary where families and friends can come together, reconnect, and reflect.Photo 1: One of Spritzer EcoPark DecorationsSpritzer’s dazzling decorations feature a blend of classic Malay motifs with floral elements through seven unique setups. Many of the designs incorporate upcycled decorations, showcasing sustainability alongside artistry. One of the setups features a lush, flower-adorned bower that adds to the enchanting atmosphere. Moon and star elements, synonymous with Islam, are also woven throughout the designs. With intricate details and glowing elements, the decorations create a captivating experience that is just as stunning during the day as it is at night. Entry to the Spritzer EcoPark remains free for all!“Celebrations are about more than just coming together; it is about understanding and highlighting things that bring joy to our lives and loved ones. This year’s theme is about celebrates thoughtfulness through simple acts of kindness and care,” said Winnie Chin, Head of Public Relations of Spritzer. “At Spritzer, we believe that true celebration comes from thoughtful gestures, whether it is spending quality time, nourishing our families, or simply creating a space for everyone to enjoy nature at its best. Spritzer EcoPark was preserved for this purpose – a legacy where people can connect, reflect, and celebrate surrounded by the tranquillity of nature.”Photo 2: Spritzer EcoPark decorations with traditional Malay elementsSpritzer EcoPark offers a variety of engaging activities for all ages to add onto the festive atmosphere. Families can enjoy mini golf, paddle kart rides, and creative DIY crafts, making this celebration one of shared laughter and meaningful connections. The Snack Station provides delicious treats at affordable prices, while the Water Shop ensures that guests can stock up on Spritzer’s refreshing products and try out the new Spritzer Hari Raya recipes for their Raya gatherings. Unique souvenirs will also be available at the Souvenir Shop, allowing visitors to take home a special memento of their time at the park.Photo 3: Spritzer EcoPark Decorations at nightWishing you a joyous Hari Raya from Spritzer EcoPark! Whether you are here for fun, relaxation, or a refreshing escape, we are ready to make your celebration even more special.The park is open daily from 10:00 AM to 9:30 PM. We are located at Lot 898, Jalan Reservoir, Off Jalan Air Kuning, 34000 Taiping, Perak.For more updates and details, follow Spritzer EcoPark on Facebook and Instagram. – End–About SpritzerSpritzer, Malaysia’s No.1 bottled water brand since 1989, sources its water from a 430-acre tropical rainforest in Taiping. The water undergoes a natural filtration process through underground rocks for over 15 years, enriching it with essential minerals like Silica, which benefits skin, bones, hair, and nails.As a leader in smart manufacturing, we use advanced technology to ensure quality and safety. Our packaging is 100% recyclable and made from recycled materials, reflecting our commitment to sustainability. Tested annually by SIRIM, our products are free from microplastics.Spritzer offers a full range of products, from Natural Mineral Water and Sparkling Water to Distilled Water and Fruit-flavoured Beverages, catering to every lifestyle and occasion. With a vision to become a circular brand by 2030, we are committed to sustainability and delivering quality you can trust.Spritzer—nature, innovation, and sustainability in every bottle. For more information, please visit www.spritzer.com.my. Copyright 2025 ACN Newswire via SeaPRwire.com.

Key Highlights:Hiring activity in Singapore saw recovery with a 3% month-on-month growth while witnessing an annual dip of 5% in February’25Advertising, Public Relations & Media sector and the Education sector lead with 7% month-on-month growth in February '25Hiring for Software, Hardware, and Telecom roles record the highest growth at 2% month-on-month Legal sector saw the strongest annual growth at 19% year-on-yearSINGAPORE, Mar 24, 2025 - (ACN Newswire via SeaPRwire.com) - foundit (formerly Monster APAC & ME), one of the leading jobs and talent platform, today published the foundit Insights Tracker (fit) Singapore for February 2025. The Singapore fit report highlights growth in the Advertising and Education sectors alongside rising demand for technology professionals.The tracker reveals an overall year-on-year (YoY) decline of 5% in hiring activity across sectors, as the index dropped from 108 in February 2024 to 103 in February 2025. However, a month-on-month (MoM) analysis indicates a 3% uptick,Commenting on Singapore's job trends for February 2025, V Suresh, CEO, foundit, said,“The February 2025 foundit Insights Tracker signals a promising recovery in Singapore’s job market. While year-on-year figures reflect ongoing economic recalibration, the month-on-month growth indicates a resurgence in hiring activity. The robust expansion of sectors such as Advertising, Media, and Education, coupled with the growing demand for technology professionals, underscores shifting industry priorities and workforce evolution. As digital transformation accelerates, Singapore’s job landscape is stabilizing, with a strong emphasis on upskilling, adaptability, and future-ready talent."Advertising, and Education sectors lead industry growth, while Engineering and Retail sectors show strong improvementsThe Advertising, Market Research, Public Relations, Media, and Entertainment sector has emerged as a frontrunner in e-recruitment activity among all monitored industries, showing a 7% MoM growth in February 2025. This growth is driven by increased digital marketing efforts and brand-building strategies.Equally impressive, the Education sector also recorded 7% MoM growth in February 2025, reflecting a continued emphasis on workforce upskilling and professional development.Following these leaders, the Engineering, Construction, and Real Estate sector showed positive trends with 6% MoM growth, while the Retail, Trade, and Logistics sector experienced 5% MoM growth, both driven by sustainability initiatives and evolving business needs.Several sectors show modest growth while others remain stableThe Production/Manufacturing, Automotive, and Ancillary sector demonstrated positive hiring momentum with 5% MoM growth in February 2025.Several sectors showed more modest growth, with Hospitality & Travel, IT, Telecom/ISP, and BPO/ITES, BFSI, and Healthcare all registering 2% MoM increases, signalling steady job creation across these industries.Conversely, multiple sectors including Oil and Gas, Import/Export, Shipping/Marine, Government/PSU/Defence, and Consumer Goods/FMCG exhibited stagnant hiring activity with 0% MoM change.Technology roles lead demand among functionsIn terms of functions, Software, Hardware, and Telecom witnessed the highest demand in February 2025, with a 2% MoM increase. This trend underscores the growing need for tech talent amid ongoing digital transformation initiatives.Marketing & Communications, HR & Admin, Engineering/Production, Sales & Business Development, Medical Roles, and Legal roles all showed modest but positive growth at 1% MoM, indicating broad but measured hiring activity across professional functions.The roles in Legal experienced a robust   19% YoY increase in hiring activity, highlighting the rising need for legal professionals amid evolving regulatory landscapes, corporate expansions, and compliance requirements.However, Hospitality Roles, Customer Service, Finance & Accounts, and Purchase/Logistics/Supply Chain roles saw no changes (0% MoM), reflecting a period of stability in workforce demand across these functions.The foundit Insights Tracker is a comprehensive monthly analysis of online job posting activity conducted by foundit. Based on a real-time review of millions of employer job opportunities culled from a large, representative selection of online career outlets, the foundit Insights Tracker (FIT) presents a snapshot of employer online recruitment activity nationwide.About foundit - APAC & Middle Eastfoundit, formerly Monster (APAC & ME), is Asia’s leading jobs and talent platform offering comprehensive employment solutions to recruiters and job seekers across APAC & ME. In addition to its innovative AI-powered job search, foundit offers e-learning, assessments, and services related to resume creation and interview preparation. foundit has connected over 120 million job seekers across 18 countries with the right job roles and upskilling opportunities. Over the last two decades, the company has been a leader in the world of recruitment solutions and has launched cutting-edge tools to give recruiters access to passive candidates in addition to active ones. With its advanced technology, foundit is efficiently bridging the talent gap across industry verticals, experience levels, and geographies.Today, foundit is committed to enabling and connecting the right talent with the right opportunities by harnessing the power of deep tech to sharpen hyper-personalised job searches and offer precision hiring. Additionally, foundit has been recognised as a Great Place to Work, reflecting its dedication to fostering a supportive and dynamic work culture.To learn more about, foundit in APAC & Gulf, visit: www.foundit.sg |www.foundit.com.ph | www.foundit.my | www.foundit.in | www.founditgulf.com | http://www.foundit.hk | www.foundit.id For media inquiries or further information, please contactNamrata Sharma – Namrata.sharma@adfactorspr.comContact number - +65 81383034 Copyright 2025 ACN Newswire via SeaPRwire.com.

香港, 2025年3月24日 - (亞太商訊 via SeaPRwire.com) - 「十四五」開篇以來，能源央企深入落實習近平總書記關於能源安全和綠色發展的一系列重要論述，統籌「保障能源安全」和「綠色低碳轉型」兩大任務，積極貫徹國家「雙碳」戰略，全力推動高質量發展。中國電力（02380）作為國家電投旗下清潔能源旗艦上市平台，是電力企業清潔轉型和高質量發展方面最具有代表性的上市公司之一。智通財經APP了解到，中國電力3月20日發佈2024年業績公告，並在3月21日召開業績發佈會。該公司全年實現收入542.13億元，同比增長22.48%，其中清潔能源收入322億元，佔總收入60%，同比提升了9個百分點。實現權益持有者應占利潤38.62億元，經營性淨利潤創上市以來歷史新高。合併裝機容量達到4939.1萬千瓦，其中清潔能源佔比80.12%。該公司計劃宣派2024年度股息人民幣0.162元/股，派息率60%；加上2024中期特別股息0.05元/股，全年派息總額0.212元/股，派息率達到78%，對應股息率超過7.7%。四年「翻一番」，能源轉型和業績增長全面提速2021年，中國電力發佈全新戰略，步入清潔發展和創新驅動的轉型快車道，清潔能源裝機佔比快速提升、資產質量持續優化、科技創新形成新的支撐，形成了清潔發展與科技創新「雙輪驅動」、水火風光協同互濟的發展格局。存量提質方面，成功對超600萬千瓦虧損煤電開展煤電聯營，快速堵住經營業績「出血點」，煤電板塊度電盈利能力已從行業中下游躍升至領先地位。從轉型的成效來看，2021年以來，該公司實現4年「翻一番」：合併裝機容量增加85%，資產總額增加118%，營業收入增長91%，歸母淨利潤增長126%。數據來源：公司財報聚焦科技創新與核心競爭力，紮實推進戰新產業發展2021年以來，中國電力科技創新全面提速，在新型儲能、儲能安全、新型電力系統建設關鍵技術等領域掌握了一批技術。在新型儲能領域，新源智儲已獲評北京市「獨角獸」，牽頭建設應急管理部電化學儲能安全重點實驗室，推出了「智儲-銀河」系列超分子全浸沒式工商業儲能一體機，從源頭上切斷了發生火災的可能性；在綠電交通領域，啟源芯動力市場佔有率保持行業領先，C輪融資投後估值達100億元；在清潔供暖和地熱領域，新源泰利建成房山區首個100%可再生能源供熱製冷項目，獲批共建地熱院士專家工作站。分紅金額逐年上升，以實際行動回饋股東2021-2024年，該公司每股派息從0.05元上升至0.162元，2021年利潤受到火電的影響而虧損，但該公司依舊堅持派息，2022年恢復盈利後，三年的平均派息比例超過60%。拉長周期看，根據東方Choice數據，2004年以來該公司累計派息21次，平均派息比例達56.91%，在業內處於領先水平。而在分紅的持續增長下，目前其股息率已具較大吸引力。數據來源：公司公告，2024年不包括特別股息高度重視資本市場，市值表現取得顯著突破2021年以來，中國電力密集開展資產結構調整、收購母公司資產、股權激勵、母公司增持、ESG管理、投資者關係等工作，在資本市場關注度逐漸提升。2021-2022年，中國電力股價上漲超過3倍，市值最高超過600億港幣，之後2年受大環境以及電力政策影響有所回撤。該公司管理層稱，將全面加強市值管理，落實國資委關於加強中央企業控股上市公司市值管理工作的各項意見，研究各項市值管理工具利用，加大重視股東回報。值得注意的是，該公司持續獲得各方看好：大股東國家電投近年持續開展增持；中信金融資產於2024年舉牌並獲得1名董事席位；而港股通資金也在持續流入，其中滬港通於最近60日淨買入1.62億股，截止3月21日持股比例13.78%，較2021年增長約10個百分點。此外，該公司也獲得多家境內外投行看好，給予目標價均顯著高於現價。綜合來看，「十四五」開篇至今，中國電力加速內功修煉，向市場交出了一份靚麗的成績單。在算力需求呈指數級增長導致全球開啟電力競賽的背景下，在能源政策支持電力企業高質量發展的趨勢下，電力公司在資本市場有望獲得估值回歸。而中國電力憑藉自身戰略、資產結構等差異化優勢，有望迎來更好的投資機會。 Copyright 2025 亞太商訊 via SeaPRwire.com.

SAN DIEGO, CA, Mar 21, 2025 - (ACN Newswire via SeaPRwire.com) - General Atomics Aeronautical Systems, Inc. (GA-ASI), a world leader in unmanned aircraft systems (UAS), has received the prestigious EMAR/FR 145 Maintenance Organization Approval for component maintenance from the French Military Continuing Airworthiness Authority, DSAE. This approval underscores GA-ASI's commitment to the highest standards of safety, compliance, and operational excellence in military aviation.The EMAR framework is a set of regulations developed from commercial aerospace standards (FAA/EASA) that are designed to ensure airworthiness for European military aircraft. It establishes a common airworthiness framework recognized by military airworthiness authorities worldwide. EMAR/FR 145 certification authorizes maintenance organizations to perform critical maintenance tasks while ensuring strict adherence to safety, reliability, and documentation requirements.GA-ASI's EMAR/FR 145 approval allows the company to issue EMAR Form 1s (Return to Service forms) for components serviced by the approved maintenance organization, confirming the safety and airworthiness of the equipment. This recognition applies to GA-ASI's maintenance activities at its Poway and Adelanto, California, facilities and covers CAT C (component maintenance) services."This approval is a significant achievement for GA-ASI, positioning the company to better serve international customers, especially military users of our MQ-9A and MQ-9B UAS platforms," said Sam Richardson, GA-ASI vice president of Sustainment. "The ability to leverage the EMAR/FR 145 certification streamlines the company's processes, reduces costs, and accelerates future airworthiness pursuits, as many future customers will recognize this certification rather than requiring a full, independent certification process."By obtaining EMAR/FR 145 approval, GA-ASI further demonstrates its ability to meet the stringent demands of the global defense market. The framework's widespread recognition ensures that GA-ASI can expand operations and offer high-quality, compliant maintenance services to international customers, ultimately driving company growth in global markets.This certification offers significant operational and financial benefits for both GA-ASI and its customers. For GA-ASI, the approval reduces future oversight costs by leveraging the DSAE Audit Team's oversight activities, ensuring a more efficient and cost-effective certification process for future non-French EMAR customers. For customers, the EMAR/FR 145 approval provides a framework recognized internationally, offering a streamlined maintenance certification process. The recognition agreements between EMAR and non-EMAR countries allow future customers to leverage GA-ASI's French approval, saving time and resources compared to a full certification effort.About GA-ASIGeneral Atomics Aeronautical Systems, Inc. is the world's foremost builder of Unmanned Aircraft Systems (UAS). Logging more than 8 million flight hours, the Predator® line of UAS has flown for over 30 years and includes MQ-9A Reaper®, MQ-1C Gray Eagle® 25M, MQ-20 Avenger®, and MQ-9B SkyGuardian®/SeaGuardian®. The company is dedicated to providing long-endurance, multi-mission solutions that deliver persistent situational awareness and rapid strike.For more information, visit www.ga-asi.com.Avenger, EagleEye, Gray Eagle, Lynx, Predator, Reaper, SeaGuardian, and SkyGuardian are trademarks of General Atomics Aeronautical Systems, Inc., registered in the United States and/or other countries.Contact InformationGA-ASI Media Relationsasi-mediarelations@ga-asi.com(858) 524-8101SOURCE: General Atomics Aeronautical Systems, Inc. Copyright 2025 ACN Newswire via SeaPRwire.com.

- ComfortDelGro, a leading multi-modal mobility transport operator, introduces a new purpose statement to reflect its commitment to driving positive impact for a better future. - Refreshed logo and corporate identity underscores the company’s journey as a global, progressive, and collaborative mobility leader. SINGAPORE, Mar 24, 2025 - (ACN Newswire via SeaPRwire.com) - ComfortDelGro Corporation Limited (SGX:C52) (“ComfortDelGro” or, “The Group”) today, unveiled its refreshed corporate brand, comprising a new purpose statement and modern visual identity that signifies a step forward in the company’s evolution into a global multi-modal transport leader. The Group has made significant strides in growing its international business, winning bus and rail tenders in Europe and Australia, as well as building leading positions for its point-to-point mobility businesses in key markets. With a presence in 13 countries, 24,500 employees, an operating fleet of over 54,000 vehicles and a rail network of 343 kilometres in operation and under mobilisation, ComfortDelGro is one of the largest land transport companies in the world. ComfortDelGro Managing Director/Group CEO Cheng Siak Kian said, “Our purpose statement – Mobility for a better future, drives us to reimagine mobility as a catalyst for positive impact as we accelerate our growth and navigate new horizons. It reflects our commitment to addressing the changing needs of our stakeholders as a global multi-modal transport leader. At the same time, it aligns the Group’s diverse operations and workforce under the common goal of building a purpose-driven and values-led organisation.” ComfortDelGro Chairman Mark Greaves added, “The transport landscape is evolving, and so is ComfortDelGro. We are committed to sustainable mobility, powered by innovation and driven by collaboration. This brand refresh underpins our journey forward as a global, progressive, and collaborative mobility company while building on the strong foundation of our businesses and our rich heritage. Our purpose ‘Mobility for a better future’ will guide us as we continue to create long-term value for our stakeholders, shape the future of transportation, and contribute to a more sustainable and connected world." Driven by our new purpose: Mobility for a better futureA modern identityComplementing our purpose statement is an updated ComfortDelGro logo that symbolises the company’s journey forward and its commitment to delivering innovative, world-class mobility solutions. Key elements include:A refined blue hue, representing reliability, trust, and customer confidence.A streamlined lowercase font, conveying approachability and collaboration.An enhanced arrow motif, reinforcing the company’s forward-thinking and dynamic approach.The updated brand and corporate identity will be gradually implemented in stages across the Group’s global operations.Media Assets:High-resolution images can be downloaded here: https://fromsmash.com/cdgbrandrefreshAbout ComfortDelGro CorporationComfortDelGro is a leading multi-modal transport operator offering a comprehensive suite of transportation solutions. Our extensive network spans public transport including buses and rail, point-to-point transport with taxis and private hire cars as well as business-to-business mobility solutions. Every day, millions rely on our services across 13 countries including; Singapore, Australia, the United Kingdom, New Zealand, China, Ireland, Sweden, France, Malaysia, Spain, Portugal, Greece, and the Netherlands. As a global operator, we play an important role in steering the transition towards a low-carbon economy. With about 60% of our owned fleet consisting of cleaner energy vehicles, we support governments and cities in enabling inclusive and sustainable transport systems. For our efforts, ComfortDelGro has been included in the Dow Jones Best-in-Class Indices since 2019, the only Singaporean transport company in the index. Media Contact Information:Group Corporate Communications  ComfortDelGro Corporation Limited groupcorpcomms@comfortdelgro.com  Copyright 2025 ACN Newswire via SeaPRwire.com.

Financial Highlights For the Year Ended 31 December RMB20242023Change RMB’BillionRMB’Billion(%)Revenue28.8726.20+10.2%Gross profit margin (%)81.5%81.0%+0.5pptSelling and administrative expenses to revenue ratio (%) *42.1%42.2%-0.1pptR&D expenses to revenue ratio (%)17.6%16.8%+0.8pptProfit for the year6.365.10+24.9%Profit attributable to owners of the parent **3.502.33+50.1%Adjusted non-HKFRS profit attributable tothe owners of the parent *** 3.46 2.59 +33.5%Basic earnings per share, based on adjusted non-HKFRS profit attributable to the owner of the parent (RMB cents) 18.90 13.97 +35.3%Sales of innovative products ****12.069.89+21.9%Share of revenue (%)41.8%37.8% Sales of new products*****10.098.05+25.4%Share of revenue (%)35.0%30.7% Dividend per share (HK cents)7.05.0+40.0%- Interim3.02.0+50.0%- Final4.03.0+33.3%*The total of selling and distribution costs and administrative expenses divided by revenue**The significant year-on-year increase in profit attributable to the owners of the parent was mainly driven by the notable growth in revenue and the gain on disposal of subsidiaries during the year***It refers to the basic earnings attributable to the owners of the parent after excluding impacts of discontinued operations, certain non-cash items and the share of profits and losses of associates and joint ventures.****Sales is the gross sales amount minus the sales discount. Innovative products include innovative drugs and biosimilars*****Products launched within five yearsDevelopment HighlightsOncology Innovative Drugs- Focus V (Anlotinib Hydrochloride Capsules) has been approved for seven indications. The marketing applications of three new indications have been submitted to the Center for Drug Evaluation of the China National Medical Products Administration (“CDE”), while another three pivotal clinical trials for new indications have shown positive results. The Group will submit new marketing applications to the CDE for these indications in the near future. In addition, anlotinib is in Phase III clinical studies for a number of new indications, including first-line non-squamous non-small cell lung cancer and first-line colorectal cancer. It is expected that marketing applications will be submitted gradually in the next few years.- Yilishu (Efbemalenograstim alfa Injection) has completed three global multi-center, randomized, and controlled pivotal Phase III clinical trials, and has been compared with the commonly used short-acting and long-acting G-CSF drugs in clinical practice, proving its efficacy and safety. In December 2023, Efbemalenograstim alfa was successfully included in the NRDL, and its sales volume accelerated in 2024, becoming an important contributor to the Group’s revenue growth.- Anfangning (Garsorasib Tablets) is a novel and highly effective KRAS G12C inhibitor that was approved for marketing by the NMPA in November 2024 for the treatment of advanced non-small cell lung cancer with KRAS G12C mutation that has received at least one systemic treatment. The Group will further explore the multi-indication potential of garsorasib, which is expected to become another blockbuster product in the oncology field.- Anbeisi (Bevacizumab Injection), Delituo (Rituximab Injection), Saituo (Trastuzumab for Injection), and Paletan (Pertuzumab Injection) were approved for marketing by the NMPA in February 2023, May 2023, July 2023, and December 2024, respectively. The rapid increase in the volume of these biosimilars in 2024 has accelerated the Group’s revenue growth.Liver Disease Innovative Drugs- Tianqing Ganmei (Magnesium Isoglycyrrhizinate Injection) is the fourth-generation of glycyrrhizic acid preparation that has been approved for three indications: chronic viral hepatitis, acute drug-induced liver injury, and improvement of liver dysfunction. Magnesium isoglycyrrhizinate is the world’s first 99.9% purified alpha-glycyrrhizic acid. It has the advantages of strong liver targeting, excellent anti-inflammatory effects, and good safety.- Lanifibranor (pan-PPAR agonist) is currently undergoing Phase III clinical trials worldwide for the treatment of metabolic dysfunction-associated steatohepatitis (MASH). In July 2023, Lanifibranor was granted Breakthrough Therapy Designation by the CDE. Lanifibranor is China’s first MASH drug to enter Phase III clinical trials and is expected to fill the gap in China’s MASH market.Respiratory Innovative Drugs- Tianqing Suchang (Budesonide Suspension for Inhalation) is China’s first budesonide nebulized generic drug approved for marketing, breaking the long-term monopoly of branded drugs in the domestic market, and offering an effective, safe and economical high-end product for patients with chronic airway inflammation in China. The product has been included in the national Volume-based Procurement (“VBP”). The Group has taken a series of proactive management measures in a timely manner, including strengthening downstream channels, expanding market coverage and conducting secondary development in markets outside the scope of the VBP, enabling its sales to achieve steady growth in 2024.- Tianyun (Colistimethate Sodium for Injection) is a first-to-market generic drug launched in 2021. It is China’s first colistimethate sodium for injection approved for marketing, and was successfully included in the NRDL in 2023. At present, only two products with the same generic name have been approved in China. The Group continued to expand its market coverage through active academic promotion, and Tianyun’s sales grew rapidly in 2024.Surgery/Analgesia Innovative Drugs- Zepolas (Flurbiprofen Cataplasms) is the first domestically produced cataplasms approved for marketing in China, ranking first in the market share of topical analgesia for many years. Sales of flurbiprofen cataplasms have maintained a growth trend in recent years and achieved breakthrough growth in 2024. The second-generation flurbiprofen patch developed by the Group is expected to be approved for marketing in 2025.Others- In 2024, the tenth batch of VBP products accounted for only 1% of the Group’s total revenue, and the related risks have basically been removed. In addition, Anboni (Unecritinib Fumarate Capsules) and Anluoqing (Envonalkib Citrate Capsules), two category 1 innovative drugs independently developed by the Group, were newly included in the NRDL and are expected to benefit more patients.HONG KONG, Mar 21, 2025 - (ACN Newswire via SeaPRwire.com) - Sino Biopharmaceutical Limited (“Sino Biopharm” or the “Company”, together with its subsidiaries, the “Group”) (HKEX:1177), a leading innovation-driven pharmaceutical conglomerate in the PRC, has announced its audited financial results for the year ended 31 December 2024.During the year, the Group recorded revenue of approximately RMB28.87 billion, an increase of approximately 10.2% over last year. Profit attributable to the owners of the parent company was approximately RMB3.50 billion, a substantial increase of approximately 50.1% over last year. Earnings per share attributable to the owners of the parent company were approximately RMB19.13 cents, a significant increase of approximately 51.9% over last year, which was mainly driven by the notable growth in revenue and the gain on disposal of subsidiaries during the year. Excluding the profit attributable to the owners of the parent from the discontinued operations, the share of profits and losses of associates and joint ventures (net of related tax and non-controlling interests), one-off adjustments for the impairment and fair value changes of certain assets and liabilities (net of related tax and non-controlling interests), fair value losses/(gains) of current equity investments (net of related tax and non-controlling interests), share-based payments (net of related tax and non-controlling interests), effective interest expenses and exchange (gain)/loss of the convertible bond debt component, adjusted non-HKFRS profit attributable to the owners of the parent was approximately RMB3.46 billion, an increase of approximately 33.5% over last year. The Group's liquidity remains strong, with total fund reserve at approximately RMB24.11 billion, including cash and bank balances classified under current assets of approximately RMB9.57 billion, bank deposit classified under non-current assets of approximately RMB9.37 billion, and the wealth management products of approximately RMB5.17 billion in aggregate.The Board of Directors has recommended a final dividend payment of HK4 cents per share (2023: HK3 cents). Together with the interim dividend of HK3 cents already paid, the total dividend for the year amounted to HK7 cents (2023: HK5 cents).Sales: Robust sales system continues to drive results  Achieves positive revenue growth for  generic drugsOn the strong foundation its generic drug business provides, the Group has comprehensively promoted innovation and transformation. The innovative products have kept boosting sales growth, with share of revenue climbing year after year. Revenue from innovative products amounted to RMB12.06 billion, up by 21.9% year-on-year, and accounted for 41.8% of the Group's total revenue.During the year, the sales of oncology medicines amounted to approximately RMB10.73 billion, representing approximately 37.2% of the Group’s revenue. The sales of surgery/analgesia and liver disease amounted to approximately RMB4.46 billion and RMB3.44 billion, respectively, representing approximately 15.4% and 11.9% of the Group's revenue, respectively. In addition, sales contributions from various areas such as respiratory, cardio-cerebral vascular medicines and others have continued to contribute to the Group's revenue. Among them, the sales of respiratory and cardio-cerebral vascular medicines accounted for approximately 10.9% and 7.5% of the Group's revenue, respectively.R&D: Pushes at full force innovative product development  Actively applies for various patentsThe Group has continued to focus its R&D efforts on new medicines in the four therapeutic areas of oncology, liver diseases, respiratory and surgery/analgesia. As at the end of the reporting period, the Group had 70 innovative products under development, including 39 oncology products, 7 liver disease products, 13 respiratory products, and 6 surgery/analgesia products, and 5 other products. In addition, the Group had 65 generic drug products in development.The Group also attaches tremendous importance to the protection of intellectual property rights and encourages its member enterprises to file patent applications in order to enhance the Group’s core competitiveness. During the reporting period, the Group filed 1,069 new patent applications and received 349 patent invention approvals. As at the end of the reporting period, the Group had accumulated 5,082 effective patents and patent applications and obtained 1,958 patent invention approvals.Prospects: Focuses on core business and innovation  Continues to promote dual-pronged approach in implementing globalization strategyThe Chinese pharmaceutical market has occupied a key position in the global pharmaceutical industry due to its huge volume and increasing market demand. In addition, as a strategic industry closely linked to the national economy and people’s livelihood, the pharmaceutical industry receives key support from national policies and incentives. Meanwhile, a series of policies is expected to broaden the pricing flexibility of innovative drugs, improve their accessibility, and create a wider market prospect for such drugs.Committed to its vision “to be a leading global pharmaceutical company through delivering innovative therapies for patients”, the Group has adhered to comprehensive innovation, stepped up its R&D investment, and continued to strengthen its internal R&D capabilities. It has now built a comprehensive pipeline and product portfolio. At the same time, the Group has vigorously promoted business development and strategic cooperation, striving to become the best partner for global pharmaceutical and biotechnology enterprises.At present, the Group has entered the harvest period of its innovative development. It is expected that by 2027, the number of innovative products launched to the market will exceed 30, with revenue from innovative products accounting for over 55% of total revenue. This will further strengthen the Group’s dominant position in the four main therapeutic areas and provide strong impetus for the future sustainable growth. In addition, the Group has advanced its digitalization strategy with artificial intelligence (AI) as the core driving force. It has finished locally deploying cutting-edge AI models including DeepSeek and ChatGPT, and optimized key business such as cross-departmental collaboration, thereby significantly improving operational efficiency.Meanwhile, the Group adopts its dual-pronged globalization strategy to accelerate innovation and development. The Group will bring global pharmaceutical innovations to China to benefit Chinese patients, while also expanding its presence in international markets to target unmet clinical needs worldwide.Looking ahead, the Group will further focus on its core business and innovation, and continue to improve R&D efficiency and quality in the four major therapeutic areas. It will also actively accelerate the deployment for globalization of its business to drive rapid business growth and steady performance improvement, and contribute to the development of the global pharmaceutical industry.About Sino Biopharmaceutical Limited (HKEX:1177)Sino Biopharmaceutical Limited is a leading Chinese pharmaceutical company continuing to invest in Oncology, Liver Diseases, Respiratory and Surgery/Analgesia, exploring innovative therapies to improve the lives of patients. The company has strong manufacturing capabilities and broad patient access across China. Sino Biopharmaceutical Limited is committed to bring innovation to address unmet healthcare needs globally. The company was listed on the Hong Kong Stock Exchange in 2000, and was selected as a component of the MSCI Global Standard Index in China in 2013; In 2018, it was selected as a constituent stock of Hang Seng Index; In 2020, it was selected as a constituent stock of Hang Seng Connect Biotech 50 Index and the Hang Seng China (Hong Kong Listed) 25 Index. The company has been listed in the “Top 50 Global Pharmaceutical Enterprises” published by the authoritative American magazine Pharmaceutical Manager for six consecutive years, and has been rated as the “Top 50 Best Companies in Asia Pacific” by Forbes (Asia) for three consecutive years.For more information, please visit: www.sinobiopharm.com Copyright 2025 ACN Newswire via SeaPRwire.com.

財務摘要︰- 2024年收益為人民幣1,141.1百萬元，較2023年同期增長25.6%。其中，綜合遊戲發行及運營業務收益同比增長45.9%至人民幣1,035.0百萬元，佔總收益的90.7%。- 2024年毛利為人民幣826.0百萬元，較2023年同期增長27.0%，毛利率為72.4%，與去年同期保持基本一致。- 2024年研發開支同比減少8.6%至人民幣532.1百萬元，銷售及營銷開支增加至人民幣565.0百萬元，主要由於報告期內《龍族：卡塞爾之門》在中國大陸上線以及《以閃亮之名》持續進行運營推進所致。- 2024年經調整虧損淨額較2023年同期收窄4.6%至人民幣270.0百萬元。營運摘要︰- 截至2024年全年業績公告發佈之日，集團在逾170個地區市場推出23款精品手遊，支持14種語言的多個地區版本，已上線遊戲的全球累計註冊用戶數超過2億人，全球累計總流水超過人民幣220億元。  - 超自由時尚女性向手遊《以閃亮之名》自上線以來，十餘次以強勁之姿躋身中國大陸iOS遊戲暢銷榜前十名。伴隨兩周年慶活動序幕拉開，遊戲不但於2025年3月4日躍居iOS遊戲暢銷榜第八，更是憑藉高質量精準呈現的大屏效果，高居iPad暢銷榜第二。截至2024年12月31日，《以閃亮之名》的全球累計註冊用戶數超過2,000萬。  - 策略卡牌類遊戲《龍族：卡塞爾之門》於2024年9月在中國大陸地區正式上線，上線首日即登頂iOS應用商店遊戲免費榜並持續霸榜一周，且連續數日衝入遊戲暢銷榜前十名，成為祖龙娱乐又一款首月流水超過人民幣1億元的自主發行產品。  - 經典MMORPG手遊《龍族幻想》以及回合制MMORPG手遊《夢幻誅仙》持續實施多維度運營策略，有效實現了產品的長線平穩運營，保持了收益的持續穩定。- 為打造不同類型及多樣化的遊戲組合，集團預期於2025年至2027年期間在全球各地推出8款包括MMORPG、放置PRG、策略卡牌及其他類型的遊戲產品，其中包括一款由虛幻引擎4打造的中國風修真題材放置RPG手遊《踏風行》以及一款回合制MMORPG遊戲項目代號：逍遙。香港, 2025年3月22日 - (亞太商訊 via SeaPRwire.com) - 祖龙娱乐有限公司（「祖龙娱乐」或「公司」，連同其附屬公司，統稱「集團」，股份代號：9990.HK）公佈其截至2024年12月31日止年度（「報告期內」）之經審核年度業績。2024年，祖龙娱乐錄得收益人民幣1,141.1百萬元，較截至2023年同期人民幣908.5百萬元增加25.6%，主要由於報告期內《龍族：卡塞爾之門》在中國大陸上線及《以閃亮之名》持續發力所致；其中，綜合遊戲發行及運營業務收益較截至2023年同期同比增長45.9%至人民幣1,035.0百萬元，佔總收益的90.7%。2024年，集團毛利為人民幣826.0百萬元，較2023年同期同比增長27.0%，毛利率為72.4%，與去年同期保持基本一致。報告期內，集團研發開支同比減少8.6%至人民幣532.1百萬元，銷售及營銷開支增加至人民幣565.0百萬元，主要由於報告期內《龍族：卡塞爾之門》在中國大陸上線及《以閃亮之名》推廣及廣告開支增加所致。受上述因素綜合影響，2024年集團經調整虧損淨額較2023年同期收窄4.6%至人民幣270.0百萬元。《以閃亮之名》驗證長線運營實力，新遊上線助力產品賽道拓展以公司新一代女性製作策劃團隊為核心研發的超自由時尚女性向手遊《以閃亮之名》，自上線以來十餘次以強勁之姿躋身中國大陸iOS遊戲暢銷榜前十名，其2025年1月的單月利潤更是創下該遊戲的歷史新高。伴隨兩周年慶活動序幕拉開，遊戲不但於2025年3月4日躍居iOS遊戲暢銷榜第八，更是憑藉高質量精準呈現的大屏效果，高居iPad暢銷榜第二，當日流水攀升至一周年慶以來的峰值。2024年，遊戲持續進行高質量的迭代更新，與中國郵政、上海海昌海洋公園、沙漠郵局等開展聯動活動；更融入了蜀繡、泉州提線木偶戲、德化白瓷、京劇、柯爾克孜族刺繡、藏羌織繡等中國非物質文化遺產定制內容。此外，寵物系統憑藉其單只可達三千萬根毛發的極致毛流感和獨特的渲染及染色工藝，疊加多樣親寵玩法，一經上線即獲得玩家廣泛關注。未來遊戲還將解鎖大地圖以及模擬經營等更多新玩法，為玩家帶來更豐富多元的遊戲體驗。《以閃亮之名》官方微博已累計獲得超過1,700萬個轉評贊，TapTap平台評分持續高達8.9分。截至2024年12月31日，《以閃亮之名》的全球累計註冊用戶數超過2,000萬。由虛幻引擎4打造的、根據《龍族》系列小說和動畫改編開發的策略卡牌類遊戲《龍族：卡塞爾之門》，於2024年9月12日在中國大陸地區正式上線。上線首日即登頂iOS應用商店遊戲免費榜並持續霸榜一周，且連續數日衝入遊戲暢銷榜前十名，成為公司又一款首月流水超過人民幣1億元的自主發行產品。該遊戲於2024年11月26日攜手金壇刻紙推出「憑秋剪意」聯動活動，將非遺瑰寶獨特魅力融合遊戲元素展現在玩家面前。值得關注的是，對於自上線以來已分別運營超過5年和8年的由虛幻引擎4驅動的MMORPG手遊《龍族幻想》以及回合制MMORPG手遊《夢幻誅仙》，憑藉多維度的運營策略持續提升了用戶體驗。這些舉措有效實現了產品的長線平穩運營，保持了收益持續穩定。多元遊戲儲備豐富產品矩陣，「研運一體」戰略延長生命周期為打造不同類型及多樣化的遊戲組合，集團預期於2025年至2027年期間在全球各地推出8款包括MMORPG、放置RPG、策略卡牌及其他類型的遊戲產品。其中，由虛幻引擎4打造的中國風修真題材放置RPG手遊《踏風行》於2025年3月開啟了新一輪付費測試，並預計將於2025年上半年在中國大陸地區正式上線，該遊戲計劃主要採用自主發行方式。另一款融合國風和卡通美学的回合制MMORPG遊戲項目代號：逍遙，計劃於2025年對外開展測試。此外，改編自《龍族》系列小說，並依托虛幻引擎5打造的開放世界MMORPG+遊戲項目代號：Odin正在有序開發中。日後，隨著產品類型由MMORPG、SLG、女性向、策略卡牌擴張至放置RPG等多品類和豐富多樣的風格，及持續完善「研運一體」的有機模式，預期公司遊戲的生命周期將進一步延長，這將對集團的收益作出更穩定及持續的貢獻。技術創新驅動產品力提升，社會責任引領企業長期價值創新是祖龙娱乐持續發展的核心動力，技術是公司不斷提升競爭力的重要支撐。作為遊戲領域的先鋒，祖龙娱乐率先將全球領先的虛幻引擎技術引入移動遊戲開發，不斷突破技術邊界，探索未知的可能性。集團不斷在大語言模型(Large Language Model，LLM)方面研究探索，並迅速開展在遊戲產品內接入及本地化部署DeepSeek的工作。同時，公司的技術團隊基於公司產品實際需求正在自主開發能夠在遊戲內嵌入高智能化NPC的模型架構，在控制成本的基礎上更快實現智能化技術的升級與玩家體驗的提升。此外，集團還在不斷積極推進AIGC(Artificial Intelligence Generated Content)與UGC(User Generated Content)融合性創作的前沿嘗試，力爭讓玩家能夠更便捷的在遊戲內進行創意表達。正是這種對技術的執著追求與創新實踐，讓祖龙娱乐屹立於行業的前沿。與此同時，作為行業中負責任且有溫度的遊戲公司，祖龙娱乐積極踐行社會責任，篤定躬行社會公益，成功開展了「鴻鵠築夢公益計劃」、「龍行公益」等活動，在文化創新、產教融合等方面取得了可圈可點的表現。展望未來，作為中國領先的遊戲研發與運營廠商，祖龙娱乐將繼續走在遊戲行業技術探索前沿，繼續堅持精品化、多品類、研運一體、全球化的核心戰略，持續開發各品類行業領先的精品遊戲，在文娛領域持續探索和思考，對市場及用戶的定位、玩家喜好、推廣策略等挖掘更深刻的認識，腳踏實地，勇敢出發，為全球玩家創造卓越的線上娛樂體驗。關於祖龙娱乐有限公司祖龙娱乐是中國手遊行業的開拓者，專注於開發優質MMORPG、SLG、女性向、策略卡牌及其他類型的手遊，開發優質手遊的實力屢經驗證，且注重核心遊戲性體驗品類的持續深耕。截至目前，祖龙娱乐在逾170個地區市場共推出23款精品手遊，支持14種語言的多個地區版本，所提供的高質量的多元遊戲組合擁有良好的市場聲譽。 Copyright 2025 亞太商訊 via SeaPRwire.com.

財務摘要 截至12月31日止年度 人民幣2024年2023年變動    人民幣億元人民幣億元%收入288.7262.0+10.2%毛利率（%）81.5%81.0%+0.5 百分點銷售及管理費用佔收入比例（%）*42.1%42.2%-0.1百分點研發費用佔收入比例（%）17.6%16.8%+0.8百分點本年度盈利63.651.0+24.9%歸屬於母公司持有者應佔盈利**35.023.3+50.1%經調整非《香港財務報告準則》歸母淨利潤***34.625.9+33.5%基於歸屬於母公司持有者之經調整非《香港財務報告準則》歸母淨利潤計算之每股基本盈利（人民幣分）18.9013.97+35.3%創新產品收入****120.698.9+21.9%佔收入比例（%）41.8%37.8% 新產品收入*****100.980.5+25.4%佔收入比例（%）35.0%30.7% 每股股息（港仙）7.05.0+40.0%-中期3.02.0+50.0%-末期4.03.0+33.3%*銷售及分銷成本加行政費用除以收入**歸屬於母公司持有者盈利同比顯著增長主要受惠於本年度收入明顯增長及錄得出售附屬公司收益***指撇除已終止經營業務、若干非現金項目以及聯營公司及合營公司之盈利及虧損之影響後的歸屬於母公司持有者基本盈利****收入為銷售額扣除銷售折扣，創新產品包含創新藥及生物類似藥*****五年內上市的產品重點成果腫瘤創新藥- 福可維（鹽酸安羅替尼膠囊）目前已獲批七個適應症。三項新適應症已向中國國家藥品監督管理局藥品審評中心（「CDE」）遞交上市申請，另有三項新適應症的關鍵性臨床試驗已取得陽性結果，集團將於近期向CDE遞交新增該等適應症的上市申請。此外，安羅替尼還有多項新適應症的臨床研究正在III期，包含一線非鱗狀非小細胞肺癌、一線結直腸癌等，預計將在未來幾年逐步遞交上市申請。- 億立舒（艾貝格司亭）注射液通過三項全球多中心、隨機、對照研究的關鍵性III期臨床試驗，與臨床上常用的短效升白藥和長效升白藥進行了對比，證明了其療效和安全性。艾貝格司亭於2023年成功納入國家醫保目錄，並在2024年加速放量，成為集團收入增長的重要貢獻品種。- 安方寧（格索雷塞片）是一款新型、高效的KRAS G12C抑制劑，於2024年11月獲得NMPA的上市批准，用於治療至少接受過一種系統性治療的KRAS G12C突變型的晚期非小細胞肺癌。集團將深入挖掘格索雷塞的多適應症潛力，有望將其打造為腫瘤領域的又一款重磅產品。- 安倍斯（貝伐珠單抗注射液）、得利妥（利妥昔單抗注射液）、賽妥（注射用曲妥珠單抗）和帕樂坦（帕妥珠單抗注射液）分別於2023年2月、2023年5月、2023年7月和2024年12月獲得NMPA的上市批准。該等生物類似藥在2024年快速放量，加速了集團的收入增長。肝病創新藥- 天晴甘美（異甘草酸鎂注射液）是第四代甘草酸製劑，目前已獲批3個適應症：慢性病毒性肝炎、急性藥物性肝損傷和改善肝功能異常。異甘草酸鎂是全球第一個99.9%的純化體甘草酸，具有肝臟靶向性強、抗炎效果優、安全性高等優勢。- 拉尼蘭諾（泛PPAR激動劑）目前正在全球開展III期臨床試驗，用於治療代謝功能障礙相關脂肪性肝炎（MASH）。2023年7月，拉尼蘭諾被CDE納入突破性治療藥物程序。拉尼蘭諾是中國第一個進入臨床III期的MASH藥物，有望填補中國市場空白。呼吸系統創新藥- 天晴速暢（吸入用布地奈德混懸液）是中國首款獲批上市的布地奈德霧化劑型仿製藥，打破了國內市場長期被原研壟斷的局面，為國內氣道慢性炎症患者帶來了兼具有效性、安全性與經濟性的高端製劑產品。該產品已被納入集采範圍，集團及時採取了一系列主動管理措施，包括管道下沉、拓展市場覆蓋和集采外市場的二次開發，使其銷售額在2024年實現了穩步增長。- 天韻（注射用多黏菌素E甲磺酸鈉）於2021年首仿上市，是中國首款獲批上市的注射用多黏菌素E甲磺酸鈉，並於2023年成功納入國家醫保目錄。目前，國內僅兩家同通用名產品獲批。集團通過積極的學術推廣，不斷拓展市場覆蓋，天韻的銷售額在2024年快速增長。外科/鎮痛創新藥- 澤普思（氟比洛芬凝膠貼膏）是中國首個獲批上市的國產凝膠貼膏，連續多年蟬聯外用鎮痛市場份額第一位。氟比洛芬凝膠貼膏的銷售額在過去幾年保持增長態勢，並在2024年實現了突破性增長。集團開發的第二代氟比洛芬貼劑預計將於2025年獲批上市。其他- 2024年，第十批集採產品僅佔本集團總收入的1%，集採風險基本出清。此外，集團自主研發的兩款1類創新藥，安柏尼（富馬酸安奈克替尼膠囊）及安洛晴（枸櫞酸依奉阿克膠囊），新增納入醫保目錄，有望惠及更多患者。香港, 2025年3月21日 - (亞太商訊 via SeaPRwire.com) - 中國領先的創新研發驅動型醫藥集團-中國生物製藥有限公司（「中國生物製藥」或「公司」，連同附屬公司統稱「集團」）（股票編號：1177）公布截至2024年12月31日止12個月之經審核財務業績。年內，集團錄得收入約288.7億元（人民幣，下同），按年增長約10.2%。歸屬於母公司持有者應佔盈利約35.0億元，按年大幅增長約50.1%。基於歸屬於母公司持有者應佔盈利計算之每股盈利約19.13分，按年顯著增長約51.9%，該顯著增長主要受惠於本年度收入明顯增長及錄得出售附屬公司收益。扣除已終止經營業務之歸屬於母公司持有者應佔盈利，應佔聯營公司及合營公司虧損（扣除相關稅項及非控制權益），若干資產及負債之公允價值變動及一次性調整之減值，流動權益投資之公允價值虧損╱（利潤）（扣除相關稅項及非控制權益），股權激勵費用（扣除相關稅項及非控制權益），可轉換債券債務部份之利息費用及匯兌（收益）╱虧損之影響後，經調整非《香港財務報告準則》歸母淨利潤約人民幣34.6億元，按年增長約33.5%。集團流動資金保持充裕，資金儲備總額約241.1億元（計入流動資產之現金及銀行結餘約95.7億元、計入非流動資產之銀行存款約93.7億元、理財管理產品總額約51.7億元）。董事會建議派發末期股息每股4港仙（2023年：3港仙），連同已派發中期股息每股3港仙，全年合共派發股息每股7港仙（2023年：5港仙）。銷售：強大銷售體系持續發力，仿製藥收入實現正增長集團以仿製為基石，全面推進創新轉型，創新產品不斷驅動銷售增量，收入佔比逐年提升。年內，創新產品收入達到120.6億元，按年增長21.9%，佔集團總收入比例達41.8%。年內，抗腫瘤用藥之收入達約107.3億元，佔集團收入約37.2%。外科╱鎮痛用藥和肝病用藥之收入分別約44.6億元和34.4億元，各佔集團收入約15.4%和11.9%。此外，呼吸系統、心腦血管用藥和其他等不同領域產品的銷售持續貢獻集團收入。其中，呼吸系統及心腦血管用藥之收入分別佔集團收入的約10.9%和7.5%。研發：全力以赴推動創新產品開發，積極申請各類專利集團繼續專注抗腫瘤、肝病、呼吸系統和外科/鎮痛四大治療領域的新產品研發。截至報告期日，集團有在研創新藥70個，其中抗腫瘤用藥39個、肝病用藥7個、呼吸系統用藥13個、外科/鎮痛用藥6個，其他類用藥5個。另外，集團還有65個在研仿製藥産品。集團亦十分重視保護知識產權，鼓勵成員企業積極申報各種專利，以提高核心競爭能力。年內，集團提交專利申請1,069項及獲得專利發明授權349項。截至報告期日，集團累計有效專利及專利申請5,082項，累計獲得專利發明授權1,958項。展望：聚焦核心業務和創新，繼續推進「雙路徑」國際化發展戰略中國醫藥市場憑藉龐大的體量與遞增的市場需求，在全球醫藥産業中占據關鍵地位。此外，醫藥産業作為關係國計民生的戰略性産業，是國家政策引導和激勵的重點扶持對象。同時，一系列的政策拓寬了創新藥的定價空間，提升了藥品可及性，創新藥有望迎來更廣闊的市場前景。集團秉承「專注創新、服務病患，成為全球領先的製藥企業」的願景，堅持全面創新，不斷加大研發投入，自主研發能力持續增强，目前已構建完善的管綫産品組合。同時，集團大力推進商務拓展和戰略合作，力爭成為全球製藥與生物科技公司的最佳合作夥伴。目前，集團已進入創新成果收穫期，預計到2027年，集團已上市創新産品數量將超過30個，創新産品收入占總收入比例將突破50%，這將强化集團在四大治療領域的優勢地位，為未來可持續發展注入强大動力。此外，集團以人工智能為核心驅動力，推動數字化戰略升級，已完成DeepSeek、ChatGPT等AI模型的本地化部署，優化跨部門協作等關鍵業務，顯著提升運營效率。同時，集團采用「雙路徑」國際化發展戰略，加速創新發展。一方面，集團通過引進全球醫藥創新成果到中國，惠及中國病患；另一方面，集團拓展國際市場，瞄準全球尚未滿足的臨床需求。未來，集團將進一步聚焦核心業務和創新，持續提升四大治療領域的研發效率和質量，並積極推進國際化佈局，驅動業務高速增長和業績穩步提升，為全球醫藥事業的發展貢獻力量。有關中國生物製藥有限公司（股票編號：1177）中國生物製藥，連同其附屬公司，是中國領先的創新研究和研發驅動型醫藥集團，業務覆蓋醫藥研發平台、智慧化生産和強大銷售體系全産業鏈。産品包括多種生物藥和化學藥，在腫瘤、肝病、呼吸系統、外科/鎮痛四大治療領域處於優勢地位。公司於2000年在香港聯交所上市，2013年入選MSCI全球標準指數之中國指數成分股；2018年入選恒生指數成分股；2020年入選恒生滬深港通生物科技50指數成分股、恒生中國(香港上市)25指數。中國生物製藥連續五年榮登美國權威雜志《製藥經理人》發布的「全球製藥企業TOP50」，連續三年獲評《福布斯》(亞洲) 「亞太最佳公司50強」。有關中國生物製藥的進一步資料，請瀏覽:www.sinobiopharm.com Copyright 2025 亞太商訊 via SeaPRwire.com.